Compounds for treating cancer

ABSTRACT

A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: 
                         
where:
         R independently represents a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1  group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2  group, a —NR 1 R 2  group, or a (C 1 -C 3 )alkoxy group;   R′ is a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkyl group, a —NO 2  group, a (C 1 -C 3 )alkoxy group, or a —NR 1 R 2  group; and   R 1  and R 2  are a hydrogen atom or a (C 1 -C 3 )alkyl group.

This is a continuation of U.S. application Ser. No. 14/087,762 filedNov. 22, 2013, which is a continuation of application Ser. No.13/377,745 filed Jul. 5, 2012, which is a National Stage Application ofPCT/IB2010/052560 filed Jun. 14, 2010, and claims the benefit of U.S.Provisional Application Nos. 61/186,552 filed Jun. 12, 2009 and61/186,544 filed Jun. 12, 2009 and European Application Nos. 09305540.8filed Jun. 12, 2009 and 09162630.9 filed Jun. 12, 2009. The entiredisclosures of the prior applications are hereby incorporated byreference herein in their entirety.

FIELD OF THE INVENTION

The present disclosure is generally directed to the manufacture and useof compounds to treat cancer.

BACKGROUND OF THE INVENTION

In most cancers, mortality is not due to the primary tumor but rather tothe derived metastases. This malignant progression is clinically definedby the appearance of metastatic cells. Tumor metastases are typicallydefined by a primary loss of cell adhesion and an increase of cellmotility, which allows for invasive cell to leave the initial tumor siteand colonize various target tissues.

Metastases are considered as a recurrent feature of uncontrolledmalignant progression of cancer. During this process, tumor cellscomplete their malignant transformation by increasing their migratorycapacity. Cancer cells can then disseminate and establish new tumor fociin far away sites. This event is termed “metastatic cascade,” which, asindicated immediately above, is marked by invasion of tissues around thetumor, venous or lymphatic intravasation, migration and establishment ofnew tumors in distant places of an organism that may escape from allinnate defense mechanisms.

Because no efficient therapeutic options presently exist for thetreatment or prevention of metastatic tumors, metastatic invasion amajor cause of death worldwide. Due to the frequency of cancersdiagnosed at the metastatic stage and the lack of viable therapeuticoptions at this stage of the disease, the development of molecules thatspecifically target metastatic invasion is crucial for a majorbreakthrough in cancer treatments.

The compounds and methods of use as described herein are consistent withnumerous published reports during the last twenty years that demonstratea link between changes in RNA alternative splicing and metastaticinvasion, which has opened new avenues for therapeutic strategies.

SUMMARY OF THE INVENTION

As discussed in further detail below and as shown in the workingexamples, formula (I) and derivatives thereof are able to correctdefects of alternative splicing, a mechanism closely associated with theinvasive progression of metastatic. cancers. Thus, in certain aspects,the compounds described herein may be useful for preventing, inhibiting,or treating cancer.

In certain aspects, the compounds described herein further relate to amethod of preventing, inhibiting or treating cancer. For example, themethod can include administering an effective amount of a compoundhaving formula (I) or any derivative thereof as described below or oneof its pharmaceutically acceptable salts to a patient.

As described in greater detail below, the compounds described herein canbe included in pharmaceutical compositions.

DETAILED DESCRIPTION OF THE INVENTION

According to a first aspect, the subject-matter described herein relatesto a compound of formula (I)

-   -   wherein:

means an aromatic ring wherein V is C or N and when V is N, V is in anortho, meta or para position with respect to Z, i.e. forms respectivelya pyridazine, a pyrimidine or a pyrazine group,

-   -   R independently represents a hydrogen atom, a halogen atom or a        group chosen among a —CN group, a hydroxyl group, a —COOR₁        group, a (C₁-C₃)fluoroalkyl group, a (C₁-C₃)fluoroalkoxy group,        a —NO₂ group, a —NR₁R₂ group, a (C₁-C₄)alkoxy group, a phenoxy        group and a (C₁-C₃)alkyl group, the alkyl being optionally        mono-substituted by a hydroxyl group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   n is 1, 2 or 3,    -   n′ is 1 or 2,    -   R′ is a hydrogen atom or a group chosen among a (C₁-C₃)alkyl        group, a halogen atom, a hydroxyl group, a —COOR₁ group, a —NO₂        group, a —NR₁R₂ group, a morpholinyl or a morpholino group, a        N-methylpiperazinyl group, a (C₁-C₃)fluoroalkyl group, a        (C₁-C₄)alkoxy group and a —CN group,    -   R″ is a hydrogen atom or a (C₁-C₄)alkyl group,    -   Z is N or C,    -   Y is N or C,    -   X is N or C,    -   W is N or C,    -   T is N or C,    -   U is N or C,    -   and wherein at most four of the groups V, T, U, Z, Y, X and W        are N,    -   and at least one of the groups T, U, Y, X and W is N,    -   or anyone of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

According to one aspect, formula (I) as defined above includes acompound wherein Z is N, V is C, Y is N, X is C, T is C, U is C and W isC, which can be used as an agent for preventing, inhibiting or treatingcancer.

According to another aspect, formula (I) as defined above includes acompound wherein Z is C, V is C, Y is N, X is C, T is C, U is C and W isC, which can be used as an agent for preventing, inhibiting or treatingcancer.

According to another aspect, formula (I) as defined above includes acompound wherein Z is N, V is C, Y is C, X is N, T is C, U is C and W isC, which can be used as an agent for preventing, inhibiting or treatingcancer.

According to another aspect, formula (I) as defined above includes acompound wherein Z is N, V is C, Y is C, X is C, T is C, U is C and W isN, which can be used as an agent for preventing, inhibiting or treatingcancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is N and is in the para position withrespect to Z, Y is N, X is C, T is C, U is C and W is C, which can beused as an agent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is C, V is N and is in the para position withrespect to Z, Y is C, X is N, T is C, U is C and W is C, which can beused as an agent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is C, V is N and is in the meta position withrespect to Z and is in the para position with respect to the bond linkedto NR″, Y is N, X is C, T is C, U is C and W is C, for use as an agentfor preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is C, V is N and is in the meta position withrespect to Z and is in the para position with respect to the bond linkedto NR″, Y is C, X is N, T is C, U is C and W is C, for use as an agentfor preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is C, V is C, Y is C, X is N, T is C, U is C and Wis C, for use as an agent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is C, V is C, Y is N, X is N, T is C, U is C and Wis C, for use as an agent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is N and is in the meta position withrespect to Z and in the ortho position with respect to the bond linkedto NR″, Y is N, X is C, T is C, U is C and W is C, for use as an agentfor preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is N and is in the para position withrespect to Z, Y is C, X is C, T is C, U is C and W is N, for use as anagent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is N and is in the para position withrespect to Z, Y is C, X is N, T is C, U is C and W is C, for use as anagent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is C, Y is N, X is N, T is C, U is C and Wis C, for use as an agent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is N and is in the meta position withrespect to Z and is in the ortho position with respect to the bondlinked to NR″, Y is N, X is N, T is C, U is C and W is C, for use as anagent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is C, V is C, Y is C, X is C, T is N, U is C and Wis C, for use as an agent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is C, Y is C, X is C, T is N, U is C and Wis C, for use as an agent for preventing, inhibiting or treating cancer.

According to another aspect, formula (I) as defined above includes acompound, wherein Z is N, V is C, Y is C, X is C, T is C, U is N and Wis C, for use as an agent for preventing, inhibiting or treating cancer.

According to one preferred aspect, formula (I) as defined above, whereinZ is N, V is C, Y is N, X is C, T is C, U is C and W is C, for use as anagent for preventing, inhibiting or treating cancer.

According to another preferred aspect, formula (I) as defined aboveincludes a compound, wherein Z is N, V is N and is in the para positionwith respect to Z, Y is N, X is C, T is C, U is C and W is C, for use asan agent for preventing, inhibiting or treating cancer.

According to another preferred aspect, formula (I) as defined aboveincludes a compound, wherein Z is C, V is C, Y is C, X is C, T is N, Uis C and W is C, for use as an agent for preventing, inhibiting ortreating cancer.

According to another preferred aspect, formula (I) as defined aboveincludes a compound, wherein Z is N, V is C, Y is C, X is C, T is C, Uis N and W is C, for use as an agent for preventing, inhibiting ortreating cancer.

The compounds described herein may exist in the form of free bases or ofaddition salts with pharmaceutically acceptable acids.

The compounds of formula (I) can include physiologically acceptable acidaddition salts such as hydrobromide, tartrate, citrate,trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate,mesylate, formate, acetate and fumarate.

The compounds of formula (I) and or salts thereof may form solvates(e.g. hydrates) and the compounds describe herein can include all suchsolvates.

In the context of the present disclosure, the term:

-   -   “halogen” is understood to mean chlorine, fluorine, bromine, or        iodine, and in particular denotes chlorine, fluorine or bromine,    -   “(C₁-C₃)alkyl” as used herein respectively refers to C₁-C₃        normal, secondary or tertiary saturated hydrocarbon. Examples        are, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl,    -   “(C₁-C₃)alkoxy” as used herein respectively refers to        O—(C₁-C₃)alkyl moiety, wherein alkyl is as defined above.        Examples include, but are not limited to, methoxy, ethoxy,        1-propoxy, 2-propoxy,    -   “fluoroalkyl group” and “fluoroalkoxy group” refers respectively        to alkyl group and alkoxy group as above-defined, the groups        being substituted by at least one fluorine atom. Examples of        perfluoroalkyl groups include, but are not limited to,        trifluoromethyl or perfluoropropyl.    -   “patient” may extend to humans or mammals. For example, the term        “patient” can include cats or dogs.

In one aspect, the compounds described herein include a compound offormula (Ia)

-   -   wherein:    -   R independently represent a hydrogen atom, a halogen atom or a        group chosen among a (C₁-C₃)alkyl group, a —CN group, a hydroxyl        group, a —COOR₁ group, a (C₁-C₃)fluoroalkyl group, a —NO₂ group,        a —NR₁R₂ group and a (C₁-C₃)alkoxy group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom, a halogen atom or a group chosen among a        (C₁-C₃)alkyl group, a —NO₂ group, a (C₁-C₃)alkoxy group and a        —NR₁R₂ group,    -   R₁ and R₂ are a hydrogen atom or a (C₁-C₃)alkyl group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ib)

-   -   wherein:    -   R independently represent a hydrogen atom, a halogen atom or a        group chosen among a (C₁-C₃)alkyl group, a —NR₁R₂ group, a        (C₁-C₃)fluoroalkoxy group, a —NO₂ group, a phenoxy group and a        (C₁-C₄)alkoxy group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is preferably 1 or 2,    -   n′ is as defined above and is preferably 1,    -   R′ is a hydrogen atom, a halogen atom or a group chosen among a        (C₁-C₃)alkyl group and a (C₁-C₄)alkoxy group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ic)

-   -   wherein:    -   R independently represent a hydrogen atom or a group chosen        among a (C₁-C₃)alkyl group, a (C₁-C₃)fluoroalkyl group, a —NR₁R₂        group, a —COOR₁ group, a —NO₂ group and a (C₁-C₃)alkoxy group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Id)

-   -   wherein:    -   R independently represents a hydrogen atom or a group chosen        among a (C₁-C₃)alkyl group, a (C₁-C₃)fluoroalkyl group and a        (C₁-C₃)alkoxy group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In certain aspects, the compounds described herein include a compound offormula (Ie)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom, a halogen atom or a group chosen among a        (C₁-C₃)alkyl group and a (C₁-C₃)alkoxy group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In another aspect, the compounds described herein include a compound offormula (If)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ig)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom or a halogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ih)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ii)

-   -   wherein:    -   R independently represents a hydrogen atom or a group chosen        among a (C₁-C₃)fluoroalkoxy group and a (C₁-C₃)alkoxy group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (ID

-   -   wherein:    -   R independently represents a hydrogen atom or a group chosen        among a (C₁-C₃)fluoroalkoxy group and a (C₁-C₃)alkyl group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ik)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom, a halogen atom or a (C₁-C₃)alkyl group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Il)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Im)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Io)

-   -   wherein:    -   R independently represent a hydrogen atom or a halogen atom or a        group chosen among, a —NO₂ group, a —CN group and a (C₁-C₃)alkyl        group, said alkyl being optionally mono-substituted by a        hydroxyl group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom, a halogen atom or a (C₁-C₃)fluoroalkyl        group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ip)

-   -   wherein:    -   R represents a hydrogen atom,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Iq)

-   -   wherein:    -   R independently represents a hydrogen atom, a (C₁-C₃)alkoxy        group or a (C₁-C₃)fluoroalkoxy group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom or a group chosen among a —NR₁R₂ group, a        N-methylpiperazinyl group, a (C₁-C₃)alkoxy group and a        morpholino group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Ir)

-   -   wherein:    -   R independently represents a hydrogen atom or a (C₁-C₃)alkyl        group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 1,    -   R′ is a hydrogen atom or a group chosen among a —NR₁R₂ group, a        morpholino group and a (C₁-C₃)alkoxy group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In one aspect, the compounds described herein include a compound offormula (Iee)

-   -   wherein:    -   R independently represents a hydrogen atom, a (C₁-C₃)alkyl group        or a (C₁-C₃)fluoroalkyl group,    -   R″ is as defined above and is advantageously a hydrogen atom,    -   n is as defined above and is advantageously 1,    -   n′ is as defined above and is advantageously 2,    -   R′ is a hydrogen atom or a (C₁-C₃)alkyl group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

Among the previous defined families of compounds of formulae (Ia) to(Iee), some are more particularly preferred for their use as an agentfor preventing, inhibiting or treating cancer. These preferred compoundsparticularly belong to formulae (Ia), (Ie), (Iq) and (Iee), as definedabove or one of its pharmaceutically acceptable salts.

Accordingly, the portions below further relate to a compound chosenamong compounds of formulae (Ia), (Ie), (Iq) and (Iee), and theirpharmaceutically acceptable salts for use as an agent for preventing,inhibiting or treating cancer.

In certain aspects, the compounds described herein include a compound offormula (Ia)

-   -   wherein:    -   R independently represents a hydrogen atom, a halogen atom or a        group chosen among a (C₁-C₃)alkyl group, a —CN group, a —COOR₁        group and a (C₁-C₃)fluoroalkyl group,    -   R″ is as defined above and more preferably is a hydrogen atom,    -   R₁ is as defined above,    -   n is as defined above,    -   n′ is as defined above,    -   R′ is a halogen atom, a (C₁-C₄)alkyl group, a (C₁-C₄)alkoxy        group or a —NO₂ group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In certain aspects, the compounds described herein include a compound offormula (Ie)

-   -   wherein:    -   R represents a hydrogen atom or a (C₁-C₄)alkyl group,    -   R″ is as defined above and more preferably is a hydrogen atom,    -   n is as defined above,    -   n′ is as defined above,    -   R′ is a halogen atom,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In certain aspects, the compounds described herein include a compound offormula (Iq)

-   -   wherein:    -   R′, R″, n and n′ are as defined in formula (I), and    -   R is a (C₁-C₃)fluoroalkoxy group,    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In certain aspects, the compounds described herein include a compound offormula (Iee)

-   -   wherein:    -   R is independently a hydrogen atom or a (C₁-C₄)alkyl group,    -   R′, R″, n and n′ are as defined in formula (I),    -   or one of its pharmaceutically acceptable salt,    -   for use as an agent for preventing, inhibiting or treating        cancer.

In certain aspects, the compounds described herein include a compound offormula (Ia) or (Ie) as defined above or one of its pharmaceuticallyacceptable salts, for use as an agent for preventing, inhibiting ortreating cancer.

According to a preferred embodiment, the compounds described herein foruse as an agent for preventing, inhibiting or treating cancer, is chosenfrom:

-   (1) (8-Chloro-quinolin-2-yl)-pyridin-2-yl-amine-   (2) 2-(Quinolin-2-ylamino)-isonicotinic acid-   (3) (4-Methyl-pyridin-2-yl)-quinolin-2-yl-amine-   (4) Pyridin-2-yl-quinolin-2-yl-amine-   (5) 2-(8-Chloro-quinolin-2-ylamino)-isonicotinic acid-   (6) (8-Chloro-quinolin-2-yl)-(4-methyl-pyridin-2-yl)-amine-   (7) 6-(Quinolin-2-ylamino)-nicotinonitrile-   (8) Quinolin-2-yl-(4-trifluoromethoxy-phenyl)-amine-   (9) Pyridin-2-yl-quinolin-3-yl-amine-   (10) (3-Methoxy-pyridin-2-yl)-quinolin-3-yl-amine-   (11) Quinolin-3-yl-(5-trifluoromethyl-pyridin-2-yl)-amine-   (12) (5-Nitro-pyridin-2-yl)-quinolin-3-yl-amine-   (13) (5-Methyl-pyridin-2-yl)-quinolin-3-yl-amine-   (14) 2-(Quinolin-3-ylamino)-isonicotinic acid-   (15) Quinolin-6-yl-(5-trifluoromethyl-pyridin-2-yl)-amine-   (16) (6-Methyl-pyridin-2-yl)-quinolin-6-yl-amine-   (17) N-(6-methylpyridin-2-yl)quinolin-2-amine-   (18) 8-chloro-N-(6-methylpyridin-2-yl)quinolin-2-amine-   (19) 4-methyl-N-(pyridin-2-yl)quinolin-2-amine-   (20) 4-methyl-N-(4-methylpyridin-2-yl)quinolin-2-amine-   (21) 3-methyl-N-(4-methylpyridin-2-yl)quinolin-2-amine-   (22) 3-methyl-N-(pyridin-2-yl)quinolin-2-amine-   (23) 6-((4-methylquinolin-2-yl)amino)nicotinonitrile-   (24) 6-((3-methylquinolin-2-yl)amino)nicotinonitrile-   (25) 6-chloro-N-(4-methylpyridin-2-yl)quinolin-2-amine-   (26) 6-chloro-N-(6-methylpyridin-2-yl)quinolin-2-amine-   (27) 4-methyl-N-(5-nitropyridin-2-yl)quinolin-2-amine-   (28) N-(3-nitropyridin-2-yl)quinolin-2-amine-   (29) 8-chloro-N-(3-nitropyridin-2-yl)quinolin-2-amine-   (30) 2-((4-methylquinolin-2-yl)amino)nicotinonitrile-   (31) N-(3-methylpyridin-2-yl)quinolin-2-amine-   (32) N-(5-methylpyridin-2-yl)quinolin-2-amine-   (33) 2-(quinolin-2-ylamino)isonicotinonitrile-   (34) N-(5-(trifluoromethyl)pyridin-2-yl)quinolin-2-amine-   (35) 8-chloro-N-(3-methylpyridin-2-yl)quinolin-2-amine-   (36) 8-chloro-N-(5-methylpyridin-2-yl)quinolin-2-amine-   (37) 8-chloro-N-(5-(trifluoromethyl)pyridin-2-yl)quinolin-2-amine-   (38) N-(3-methoxypyridin-2-yl)quinolin-2-amine-   (39) N-(5-nitropyridin-2-yl)quinolin-2-amine-   (40) 6-((8-chloroquinolin-2-yl)amino)nicotinonitrile-   (41) N-(5-fluoropyridin-2-yl)quinolin-2-amine-   (42) N-(6-(trifluoromethyl)pyridin-2-yl)quinolin-2-amine-   (43) 8-chloro-N-(5-fluoropyridin-2-yl)quinolin-2-amine-   (44) 2-((8-chloroquinolin-2-yl)amino)nicotinic acid-   (45) 4-methyl-N-(6-methylpyridin-2-yl)quinolin-2-amine-   (46) 3-methyl-N-(6-methylpyridin-2-yl)quinolin-2-amine-   (47) 5-cyano-2-(quinolin-2-ylamino)pyridin-1-ium chloride-   (48) 2-((8-chloroquinolin-2-yl)amino)-4-methylpyridin-1-ium chloride-   (49) 8-chloro-N-(4-ethylpyridin-2-yl)quinolin-2-amine-   (50) 8-chloro-N-(6-ethylpyridin-2-yl)quinolin-2-amine-   (51) 8-chloro-N-(4,6-dimethylpyridin-2-yl)quinolin-2-amine-   (52) 6-((8-chloroquinolin-2-yl)amino)-2-methylnicotinonitrile-   (53) 8-chloro-N-(4-chloropyridin-2-yl)quinolin-2-amine-   (54) 8-methyl-N-(4-methylpyridin-2-yl)quinolin-2-amine-   (55) N-(5-bromo-4-methylpyridin-2-yl)-8-chloroquinolin-2-amine-   (56) 8-chloro-N-(3-ethyl-6-methylpyridin-2-yl)quinolin-2-amine-   (57) 8-fluoro-N-(4-methylpyridin-2-yl)quinolin-2-amine-   (58) 8-bromo-N-(4-methylpyridin-2-yl)quinolin-2-amine-   (59) methyl 6-(quinolin-2-ylamino)nicotinate-   (60) methyl 6-[(8-chloroquinolin-2-yl)amino]pyridine-3-carboxylate-   (61) methyl 6-[(3-methylquinolin-2-yl)amino]pyridine-3-carboxylate-   (62) methyl 2-[(8-chloroquinolin-2-yl)amino]pyridine-3-carboxylate-   (63) 8-methoxy-N-(4-methylpyridin-2-yl)quinolin-2-amine-   (64) N-(4-methylpyridin-2-yl)-5-nitroquinolin-2-amine-   (65) 2-N-(4-methylpyridin-2-yl)quinoline-2,8-diamine-   (66) N-(4-methylpyridin-2-yl)-5-aminoquinolin-2-amine-   (67) methyl 6-[(4-methylquinolin-2-yl)amino]pyridine-3-carboxylate-   (68) 8-chloro-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine-   (69) 2-[(8-chloroquinolin-2-yl)amino]pyridin-3-ol-   (70) 8-chloro-N-[6-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine-   (71) 6-chloro-N-(5-fluoropyridin-2-yl)quinolin-2-amine-   (72) N-(6-ethylpyridin-2-yl)-3-methylquinolin-2-amine-   (73) N-(5-fluoropyridin-2-yl)-3-methylquinolin-2-amine-   (74) 3-methyl-N-[5-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine-   (75) 4-N-(8-chloroquinolin-2-yl)-1-N,1-N-dimethylbenzene-1,4-diamine-   (76) N-(4-methoxyphenyl)quinolin-2-amine-   (77) 8-chloro-N-(4-methoxyphenyl)quinolin-2-amine-   (78) 4-methyl-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (79) N-(4-methoxyphenyl)-3-methylquinolin-2-amine-   (80) 3-methyl-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (81) 1-N,    1-N-dimethyl-4-N-(3-methylquinolin-2-yl)benzene-1,4-diamine-   (82) N-[2-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (83) N-[3-(trifluoromethoxy)phenyl]quinolin-2-amine-   (84) N-[2-(trifluoromethoxy)phenyl]quinolin-2-amine-   (85) N-(4-nitrophenyl)quinolin-2-amine-   (86) N-(3-fluorophenyl)quinolin-2-amine-   (87) 8-chloro-N-[3-(trifluoromethoxy)phenyl]quinolin-2-amine-   (88) 8-chloro-N-(3-fluorophenyl)quinolin-2-amine-   (89) 2-{[4-(trifluoromethoxy)phenyl]amino}quinolin-1-ium chloride-   (90) 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (91)    3-methyl-N-[2-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (92) 3-methyl-N-[3-(trifluoromethoxy)phenyl]quinolin-2-amine-   (93) 3-methyl-N-[2-(trifluoromethoxy)phenyl]quinolin-2-amine-   (94)    8-chloro-N-[2-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (95) 3-methyl-2-{[4-(trifluoromethoxy)phenyl]amino}quinolin-1-ium    chloride-   (96) 6-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine-   (97) 4-methyl-2-{[4-(trifluoromethoxy)phenyl]amino}quinolin-1-ium    chloride-   (98) 8-bromo-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (99) 8-fluoro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (100) 8-methyl-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (101) N-(4-butoxyphenyl)-8-chloroquinolin-2-amine-   (102) N-(4-phenoxyphenyl)quinolin-2-amine-   (103) 8-methoxy-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (104)    8-chloro-N-[3-chloro-4-(trifluoromethoxy)phenyl]quinolin-2-amine-   (105) N-(6-methylpyridin-2-yl)quinolin-3-amine-   (106) N-(3-nitropyridin-2-yl)quinolin-3-amine-   (107) N-(5-methylpyridin-2-yl)quinolin-6-amine-   (108) N-(3-methoxypyridin-2-yl)quinolin-6-amine-   (109) 6-chloro-N-(pyrazin-2-yl)quinolin-2-amine-   (110) 8-bromo-N-(pyrazin-2-yl)quinolin-2-amine-   (111) 8-methyl-N-(pyrazin-2-yl)quinolin-2-amine-   (112) 8-chloro-N-(pyrazin-2-yl)quinolin-2-amine-   (113) N-(pyrazin-2-yl)quinolin-2-amine-   (114) 4-methyl-N-(pyrazin-2-yl)quinolin-2-amine-   (115) 3-methyl-N-(pyrazin-2-yl)quinolin-2-amine-   (116) 8-fluoro-N-(pyrazin-2-yl)quinolin-2-amine-   (117) 8-methoxy-N-(pyrazin-2-yl)quinolin-2-amine-   (118) N-(pyridin-3-yl)quinolin-3-amine-   (119) 8-chloro-N-(pyridin-4-yl)quinolin-2-amine-   (120) N-(pyridin-4-yl)quinolin-2-amine-   (121) N-(pyridin-4-yl)quinolin-3-amine-   (122) N-[4-(trifluoromethoxy)phenyl]quinolin-3-amine-   (123) N-(4-methoxyphenyl)quinolin-3-amine-   (124) N-[4-(trifluoromethoxy)phenyl]quinoxalin-2-amine-   (125) N-[2-methyl-4-(trifluoromethoxy)phenyl]quinoxalin-2-amine-   (126) N-[3-(trifluoromethoxy)phenyl]quinoxalin-2-amine-   (127) N-[2-(trifluoromethoxy)phenyl]quinoxalin-2-amine-   (128) N-(pyrimidin-2-yl)quinolin-2-amine-   (129) 8-chloro-N-(pyrimidin-2-yl)quinolin-2-amine-   (130) 4-methyl-N-(pyrimidin-2-yl)quinolin-2-amine-   (131) N-(pyrazin-2-yl)quinolin-6-amine-   (132) N-(pyrazin-2-yl)quinolin-3-amine-   (133) 6-methyl-N-(naphthalen-2-yl)pyridin-2-amine-   (134) N-(naphthalen-2-yl)pyridin-2-amine-   (135) N-(pyridin-2-yl)quinoxalin-2-amine-   (136) N-(4-methylpyridin-2-yl)quinoxalin-2-amine-   (137) 6-(quinoxalin-2-ylamino)pyridine-3-carbonitrile-   (138) N-(6-methylpyridin-2-yl)quinoxalin-2-amine-   (139) N-(4-methylpyridin-2-yl)-3-(trifluoromethyl)quinoxalin-2-amine-   (140) N-(3,5-dichloro-4-methylpyridin-2-yl)quinoxalin-2-amine-   (141) N-(4-methyl-3-nitropyridin-2-yl)quinoxalin-2-amine-   (142) N-(pyrimidin-2-yl)quinoxalin-2-amine-   (143)    4-N,4-N-dimethyl-7-N-[4-(trifluoromethoxy)phenyl]quinoline-4,7-diamine-   (144)    4-(morpholin-4-yl)-N-[4-(trifluoromethoxy)phenyl]quinolin-7-amine-   (145) 4-methoxy-N-(pyridin-2-yl)quinolin-7-amine-   (146) 4-methoxy-N-(4-methylpyridin-2-yl)quinolin-7-amine-   (147)    4-N,4-N-dimethyl-7-N-(4-methylpyridin-2-yl)quinoline-4,7-diamine-   (148) 5,8-dimethyl-N-(5-methylpyridin-2-yl)isoquinolin-6-amine-   (149)    5,8-dimethyl-N-(5-trifluoromethylpyridin-2-yl)isoquinolin-6-amine-   (150) N-(4-methylpyridin-2-yl)-8-nitroquinolin-2-amine-   (151) 6-chloro-N-(6-ethylpyridin-2-yl)quinolin-2-amine-   (152) 6-chloro-N-(5-methylpyridin-2-yl)quinolin-2-amine-   (153) 6-chloro-N-[5-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine-   (154) N2-(8-chloroquinolin-2-yl)-4-methylpyridine-2,3-diamine-   (155) N-(4-butoxyphenyl)-3-methylquinolin-2-amine-   (156)    4-N-(6-chloroquinolin-2-yl)-1-N,1-N-dimethylbenzene-1,4-diamine-   (157) 8-chloro-N-(3-chloro-4-methoxyphenyl)quinolin-2-amine-   (158)    N1-(8-chloroquinolin-2-yl)-4-(trifluoromethoxy)benzene-1,2-diamine-   (159) N-(3-aminopyridin-2-yl)quinolin-3-amine-   (160) 6-chloro-N-(4-methylpyridin-2-yl)quinoxalin-2-amine-   (161) N-(4-ethylpyridin-2-yl)quinoxalin-2-amine-   (162) N-(5-bromo-4-methylpyridin-2-yl)quinoxalin-2-amine-   (163) N-(4,6-dimethylpyridin-2-yl)quinoxalin-2-amine-   (164) [2-(quinoxalin-2-ylamino)pyridin-4-yl]methanol-   (165) N-(4-methyl-5-nitropyridin-2-yl)quinoxalin-2-amine-   (166) N-(4-methoxyphenyl)-4-(4-methylpiperazin-1-yl)quinolin-7-amine-   (167) 4-methoxy-N-[4-(trifluoromethoxy)phenyl]quinolin-7-amine-   (168) N-(4-methylpyridin-2-yl)-4-(morpholin-4-yl)quinolin-7-amine-   and their pharmaceutically acceptable salts.

Among the compounds described above, compounds (6), (18), (30), (35),(36), (37), (45), (48), (51), (52), (53), (55), (56), (58), (61), (63),(64), (109), (110), (112), (143), (144) and (148) are of particularinterest.

As discussed above, the compounds described herein include compound (6),(18), (30), (35), (36), (37), (45), (48), (51), (52), (53), (55), (56),(58), (61), (63), (64), (109), (110), (112), (143), (144) and (148) orone of its pharmaceutically acceptable salts for use as an agent forpreventing, inhibiting or treating cancer.

The compounds of formulae (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig),(Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) and (Iee) cancomprise one or more asymmetric carbon atoms. They can thus exist in theform of enantiomers or of diastereoisomers. These enantiomers,diastereoisomers and their mixtures, including the racemic mixtures, areencompassed within the scope of the present invention.

The compound of formula (I) and the derivatives thereof can includetheir pharmaceutically acceptable salts, which includehydrobromide,tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate,triflate, maleate, mesylate, formate, acetate and fumarate.

In certain aspects, the compounds described herein includes compounds offormula (Ig)

-   -   wherein:    -   R independently represent a hydrogen atom, a halogen atom or a        group chosen among a (C₁-C₃)alkyl group, a —CN group, a hydroxyl        group, a —COOR₁ group, a (C₁-C₃)fluoroalkyl group, a        (C₁-C₃)fluoroalkoxy group, a —NO₂ group, a —NR₁R₂ group, and a        (C₁-C₃)alkoxy group,    -   n is 1 or 2,    -   n′ is 1 or 2,    -   R′ is a hydrogen atom or a group chosen among a (C₁-C₃)alkyl        group, a halogen atom, a hydroxyl group, a —COOR₁ group, a —NO₂        group, a —NR₁R₂ group, a (C₁-C₃)alkoxy group and a —CN group,    -   R″ is a hydrogen atom or a (C₁-C₄)alkyl group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   with the proviso that R and R′ are not simultaneously a hydrogen        atom,    -   and when n and n′ are 1 and R is a hydrogen atom then R′ is not        a —COOH group,    -   or anyone of its pharmaceutically acceptable salt.

In certain aspects, the compounds described herein includes compounds offormula (If)

-   -   wherein:    -   R independently represent a hydrogen atom, a halogen atom or a        group chosen among a (C₁-C₃)alkyl group, a —CN group, a hydroxyl        group, a —COOR₁ group, a (C₁-C₃)fluoroalkyl group, a        (C₁-C₃)fluoroalkoxy group, a —NO₂ group, a —NR₁R₂ group, and a        (C₁-C₃)alkoxy group,    -   n is 1 or 2,    -   n′ is 1 or 2,    -   R′ is a hydrogen atom or a group chosen among a (C₁-C₃)alkyl        group, a halogen atom, a hydroxyl group, a —COOR₁ group, a —NO₂        group, a —NR₁R₂ group, a (C₁-C₃)alkoxy group and a —CN group,    -   R″ is a hydrogen atom or a (C₁-C₄)alkyl group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   or anyone of its pharmaceutically acceptable salt.

In certain aspects, the compounds described herein includes compounds offormula (Ih)

-   -   wherein:

R independently represent a hydrogen atom, a halogen atom or a groupchosen among a (C₁-C₃)alkyl group, a —CN group, a hydroxyl group, a—COOR₁ group, a (C₁-C₃)fluoroalkyl group, a (C₁-C₃)fluoroalkoxy group, a—NO₂ group, a —NR₁R₂ group, and a (C₁-C₃)alkoxy group,

-   -   n is 1 or 2,    -   n′ is 1 or 2,    -   R′ is a hydrogen atom or a group chosen among a (C₁-C₃)alkyl        group, a halogen atom, a hydroxyl group, a —COOR₁ group, a —NO₂        group, a —NR₁R₂ group, a (C₁-C₃)alkoxy group and a —CN group,    -   R″ is a hydrogen atom or a (C₁-C₄)alkyl group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   or anyone of its pharmaceutically acceptable salt.

In certain aspects, the compounds described herein includes compounds offormula (Il)

-   -   wherein:    -   R independently represent a hydrogen atom, a halogen atom or a        group chosen among a (C₁-C₃)alkyl group, a —CN group, a hydroxyl        group, a —COOR₁ group, a (C₁-C₃)fluoroalkyl group, a        (C₁-C₃)fluoroalkoxy group, a —NO₂ group, a —NR₁R₂ group, and a        (C₁-C₃)alkoxy group,    -   n is 1 or 2,    -   n′ is 1 or 2,    -   R is a hydrogen atom or a group chosen among a (C₁-C₃)alkyl        group, a halogen atom, a hydroxyl group, a —COOR₁ group, a —NO₂        group, a —NR₁R₂ group, a (C₁-C₃)alkoxy group and a —CN group,    -   R″ is a hydrogen atom or a (C₁-C₄)alkyl group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   with the proviso that R and R′ are not simultaneously a hydrogen        atom,    -   or anyone of its pharmaceutically acceptable salt.

In certain aspects, the compounds described herein includes compounds offormula (Im)

-   -   wherein:

R independently represent a hydrogen atom, a halogen atom or a groupchosen among a (C₁-C₃)alkyl group, a —CN group, a hydroxyl group, a—COOR₁ group, a (C₁-C₃)fluoroalkyl group, a (C₁-C₃)fluoroalkoxy group, a—NO₂ group, a —NR₁R₂ group, and a (C₁-C₃)alkoxy group,

-   -   n is 1 or 2,    -   n′ is 1 or 2,    -   R′ is a hydrogen atom or a group chosen among a (C₁-C₃)alkyl        group, a halogen atom, a hydroxyl group, a —COOR₁ group, a —NO₂        group, a —NR₁R₂ group, a (C₁-C₃)alkoxy group and a —CN group,    -   R″ is a hydrogen atom or a (C₁-C₄)alkyl group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   with the proviso that when n and n′ are 1 and R is a hydrogen        atom, R′ is not a chlorine atom,    -   or anyone of its pharmaceutically acceptable salt.

For simplification, the following compounds and their correspondingdefinitions are called “new compounds”.

In certain aspects, the compounds described herein includes compounds offormula (Ia), as such,

-   -   wherein:    -   R″ and n are as defined in formula (Ia),    -   n′ is 1,    -   R independently represent a hydrogen atom, a halogen atom or a        group chosen among a (C₁-C₃)alkyl group, a —CN group, a hydroxyl        group, a —COOR₁ group, a (C₁-C₃)fluoroalkyl group, a —NO₂ group,        a (C₁-C₃)fluoroalkoxy group and a (C₁-C₃)alkoxy group,    -   R′ is a hydrogen atom or a halogen atom or a group chosen among        a (C₁-C₃)alkyl group, a —COOR₁ group, and a —CN group,    -   R₁ is a hydrogen atom or a (C₁-C₃)alkyl group:    -   with the proviso that    -   when R and R′ are not simultaneously a hydrogen atom,    -   when n is 1, R is not a methyl group in the ortho or para        positions with respect to Z, Z being N,    -   when R′ is a hydrogen atom, R is not a bromine atom or a        chlorine atom,    -   when R is a hydrogen atom, R′ is not a methyl or ethyl group, a        —COOH group, a COOC₂H₅ group or a bromine atom, said bromine        atom being in the ortho position with respect to the bond linked        to NR″,    -   or one of its pharmaceutically acceptable salt.

Still according to this particular embodiment, the present inventionmore particularly focuses on compounds of formula (Ia), as such,wherein,

-   -   R independently represents a hydrogen atom or a (C₁-C₃)alkyl        group,    -   R″ is as defined in formula (Ia),    -   R′ is a hydrogen atom, a halogen atom, a (C₁-C₃)alkoxy group or        a —NO₂ group,    -   n′ is 1,    -   n is 1,    -   with the proviso that    -   when n is 1, R is not a methyl group in the ortho or para        positions with respect to Z, Z being N,    -   or one of its pharmaceutically acceptable salt.

In this aspect the compounds described herein can include compounds offormula (Ia′), as such,

-   -   wherein,    -   R independently represents a hydrogen atom, a (C₁-C₃)alkyl        group, a (C₁-C₃)fluoroalkyl group, a halogen atom or a hydroxyl        group,    -   R″ is as defined in formula (Ia),    -   n is 1 or 2,    -   or one of its pharmaceutically acceptable salt.

In certain aspects, the compounds described herein includes compounds offormula (Ie)

-   -   wherein:    -   R, R′, R″ n and n′ are as defined in formula (I),    -   with the proviso that    -   when R is a hydrogen atom, R′ is not a bromine atom,    -   or one of its pharmaceutically acceptable salt.

The compounds described herein further relate to a compound of formula(Iq) as defined above, as such

-   -   wherein:    -   R, R′, R″ and n′ are as defined in formula (I),    -   n is 1 or 2,    -   with the proviso that    -   R′ and R are not simultaneously a hydrogen atom,    -   when R′ is a hydrogen atom, R is not a —NO₂ group or a —NH₂        group,    -   when n is 2 and R′ is a hydrogen atom, R is not a COOC₂H₅ group        or a chlorine atom,    -   or one of its pharmaceutically acceptable salt.

Still according to this particular embodiment, the compounds describedherein include compounds of formula (Iq), as such, wherein

-   -   R′, R″, n and n′ are as defined in formula (I), and    -   R is a (C₁-C₃)fluoroalkoxy group,    -   or one of its pharmaceutically acceptable salt.

Still according to this particular embodiment, the compounds describedherein include compounds of formula (Iq), as such, wherein

-   -   R, R″, n and n′ are as defined in formula (I), and    -   R′ is a —NR₁R₂ group,    -   R₁ and R₂ are independently a hydrogen atom or a (C₁-C₃)alkyl        group,    -   or one of its pharmaceutically acceptable salt.

Still according to this particular embodiment, the compounds describedherein include compounds of formula (Iq), as such, wherein

-   -   R, R″, n and n′ are as defined in formula (I), and    -   R′ is a morpholinyl group, a morpholino group or a        N-methylpiperazinyl group,    -   or one of its pharmaceutically acceptable salt.

In a further aspect, the compounds described herein includes a compoundof formula (Iee) as defined above, as such

-   -   wherein:    -   R, R′, R″, n and n′ are as defined in formula (I),    -   or one of its pharmaceutically acceptable salt,    -   with the exclusion of the following compound

-   -   and with the exclusion of compounds wherein R is a —NO₂ group or        a —NH₂ group when R′ is a hydrogen or a methyl group.

Still according to this particular embodiment, the compounds describedherein include compounds of formula (Iee), as such, wherein

-   -   R′, R″, n and n′ are as defined in formula (I), and    -   R is a (C₁-C₃)fluoroalkyl group,    -   or one of its pharmaceutically acceptable salt.

Among the compounds discussed above, compounds (1), (2), (5)-(8),(10)-(16), (18), (21)-(44), (46)-(75), (77)-(84), (86)-(119), (121),(124)-(130), (132), (135)-(141), (143)-(147), (149)-(168) and theirpharmaceutically acceptable salts are of particular interest.

As discussed above, the compounds described herein include compounds(1), (2), (5)-(8), (10)-(16), (18), (21)-(44), (46)-(75), (77)-(84),(86)-(119), (121), (124)-(130), (132), (135)-(141), (143)-(147),(149)-(168) and their pharmaceutically acceptable salts, as such.

More preferably, compounds (143), (144), (149), (166), (167) and theirpharmaceutically acceptable salts are of particular interest.

For example, the compounds described herein can include compounds (143),(144), (149), (166), (167) and their pharmaceutically acceptable salts,where the pharmaceutically acceptable salts include, but are not limitedto, hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate,hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetateand fumarate.

In certain aspects, the compounds described herein include compounds(143) and (144) and their pharmaceutically acceptable salts, whichinclude, but are not limited to, hydrobromide, tartrate, citrate,trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate,mesylate, formate, acetate and fumarate.

The compounds described herein, e.g. compounds of formulae (Ia), (Ie),(Iq) and (Iee) and the specific compounds as listed above, are not onlyuseful as agent for inhibiting, preventing or treating cancer but canalso be useful for inhibiting, preventing or treating premature aging orprogeria and for inhibiting, preventing or treating AIDS.

According to an aspect of the invention, the compounds may be useful toinhibit, prevent and/or treat diseases with premature aging and that arelikely related to aberrant splicing of the nuclear lamin A gene. Forexample, such diseases may include Hutchinson Guilford Progeria Syndrome(HGPS), progeria, premature aging associated with HIV infection,muscular dystrophy, Charcot-Marie-Tooth disorder, Werner syndrome, butthe diseases may also include atherosclerosis, insulin resistant type IIdiabetes, cataracts, osteoporosis and aging of the skin such asrestrictive dermopathy.

The compounds described herein can be prepared by conventional methodsof organic synthesis practiced by those skilled in the art. The generalreaction sequences outlined below represent a general method useful forpreparing the compounds of the present invention and are not meant to belimiting in scope or utility.

The compounds of general formula (I) can be prepared according to scheme1 below.

As appears in the scheme, two routes are available for recovering acompound of formula (I) according to the present invention.

The synthesis is based on a coupling reaction alternatively startingfrom a halogeno-bicycle of formula (III), wherein X, Y, W, T, U, n′, R′and R″ are as defined above and X′ is a chlorine atom or a bromine atomor from a chloro-monocycle of formula (V), wherein Z, V, n and R are asdefined above and X′ is a chlorine atom or a bromine atom.

According to route (A), the compound of formula (III) is placed in aprotic solvent such as tert-butanol. The compound of formula (IV) isthen added in a molar ratio ranging from 1 to 1.5 with respect to thecompound of formula (III) in presence of an inorganic base, such asCs₂CO₃ or K₂CO₃ in a molar ratio ranging from 1 and 2, in the presenceof a diphosphine, such as Xantphos(4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) or X-Phos(2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) in an amountranging from 2 mol % to 10 mol % relative to the total amount ofcompound of formula (III), and in the presence of a catalyst, such asPd(OAc)₂ or Pd₂dba₃ in an amount ranging from 2 mol % to 10 mol %relative to the total amount of compound of formula (III). The reactionmixture can then be heated at a temperature ranging from 80 to 120° C.,for example at 90° C. and stirred for a time ranging form 15 to 25hours, for example during 20 hours under inert gas and for exampleargon. The reaction mixture can be concentrated under reduced pressure.

According to route (B) the compound of formula (V) is placed in a proticsolvent such as tert-butanol. The compound of formula (VI) is then addedin a molar ratio ranging from 1 to 1.5 with respect to the compound offormula (V) in presence of an inorganic base, such as Cs₂CO₃ or K₂CO₃ ina molar ratio ranging from 1 to 2, in the presence of a diphosphine,such as Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) orX-Phos (2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) in anamount ranging from 2 mol % to 10 mol % relative to the total amount ofcompound of formula (V), and in the presence of a catalyst, such asPd(OAc)₂ or Pd₂dba₃ in an amount ranging from 2 mol % to 10 mol %relative to the total amount of compound of formula (V). The reactionmixture can then be heated at a temperature ranging from 80 to 120° C.,for example at 90° C. and stirred for a time ranging form 15 to 25hours, for example during 20 hours under inert gas and for exampleargon. The reaction mixture can be concentrated under reduced pressure.

The starting compounds of formula (III), (IV), (V) and (VI) arecommercially available or can be prepared according to methods known tothe person skilled in the art. The chemical structures and spectroscopicdata of some compounds of formula (I) are illustrated respectively inthe following Table I and Table II.

TABLE I (I)

Formula (Ia) 1

2

3

4

5

6

7

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

150

151

152

153

154

Formula (Ib) 8

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

155

156

157

158

Formula (Ic) 9

10

11

12

13

14

105

106

159

Formula (Id) 15

16

107

108

Formula (Ie) 109

110

111

112

113

114

115

116

117

Formula (If) 118

Formula (Ig) 119

120

Formula (Ih) 121

Formula (Ii) 122

123

Formula (Ij) 124

125

126

127

Formula (Ik) 128

129

130

Formula (Il) 131

Formula (Im) 132

Formula (Io) 135

136

137

138

139

140

141

160

161

162

163

164

165

Formula (Ip) 142

Formula (Iq) 143

144

166

167

Formula (Ir) 145

146

147

168

Formula (Iee) 148

149

TABLE II Ex Characterizations 1 MS (ESI) [M + H]⁺ = 256 2 ¹H NMR (300MHz, D₂O) δ 8.31 (d, J = 5.1, 1H), 8.21 (d, J = 9.3, 1H), 7.60 (d, J =7.5, 3H), 7.34 (dd, J = 6.2, 15.6, 2H), 7.18 (s, 1H), 6.99 (d, J = 9.1,1H) MS (ESI) [M + H]⁺ = 266 5 MS (ESI) [M + H]⁺ = 300 6 ¹H NMR (300 MHz,DMSO) δ 10.23 (s, 1H), 8.96 (s, 1H), 8.18 (d, J = 8.8, 2H), 7.78 (dd, J= 7.7, 13.7, 2H), 7.46 (d, J = 8.9, 1H), 7.31 (t, J = 7.8, 1H), 6.86 (d,J = 4.3, 1H), 2.37 (s, 3H). ¹³C NMR (75 MHz, DMSO) δ 153.63, 153.61,148.37, 147.32, 142.65, 137.52, 129.68, 129.47, 126.82, 125.06, 123.26,118.36, 115.10, 113.31, 21.24. MS (ESI) [M + H]⁺ = 270 7 ¹H NMR (300MHz, DMSO) δ 10.71 (s, 1H), 8.71 (d, J = 1.4, 1H), 8.62 (d, J = 8.9,1H), 8.24 (d, J = 8.9, 1H), 8.17 (dd, J = 1.9, 8.9, 1H), 7.89-7.74 (m,2H), 7.66 (dd, J = 7.9, 14.2, 2H), 7.42 (t, J = 7.3, 1H). ¹³C NMR (75MHz, DMSO) δ 156.09, 152.40, 152.11, 146.24, 141.07, 137.83, 129.87,127.67, 126.78, 124.50, 124.21, 118.04, 114.49, 111.67, 100.12. MS (ESI)[M + H]⁺ = 247 8 ¹H NMR (300 MHz, CDCl₃) δ 7.92 (d, J = 8.9, 1H), 7.79(d, J = 8.4, 1H), 7.65 (t, J = 7.7, 3H), 7.59 (dd, J = 7.1, 8.3, 1H),7.31 (t, J = 7.0, 1H), 7.20 (d, J = 8.5, 2H), 6.88 (d, J = 8.9, 1H),6.80 (s, 1H) ¹³C NMR (75 MHz, CDCl₃) δ 153.88, 147.62, 144.35, 139.26,138.11, 130.13, 127.65, 127.12, 124.43, 123.70, 122.20, 120.95, 112.25.MS (ESI) [M + H]⁺ = 305 10 ¹H NMR (300 MHz, CDCl₃) δ 9.10 (d, J = 2.5,1H), 8.83 (d, J = 2.6, 1H), 8.02 (d, J = 7.9, 1H), 7.94 (dd, J = 1.3,5.0, 1H), 7.85-7.79 (m, 1H), 7.52 (pd, J = 1.5, 6.9, 2H), 7.33 (s, 1H),7.04 (dd, J = 1.2, 7.9, 1H), 6.81 (dd, J = 5.1, 7.9, 1H), 3.95 (s, 3H)11 MS (ESI) [M + H]⁺ = 290 12 ¹H NMR (300 MHz, CDCl₃) δ 9.18 (d, J =2.7, 1H), 8.86 (d, J = 2.5, 1H), 8.56 (d, J = 2.3, 1H), 8.33 (dd, J =2.7, 9.2, 1H), 8.08 (d, J = 8.5, 1H), 7.83 (d, J = 8.5, 1H), 7.71-7.63(m, 2H), 7.57 (t, J = 7.4, 2H), 6.82 (d, J = 9.1, 1H) 13 ¹H NMR (300MHz, CDCl₃) δ 8.83 (d, J = 2.6, 1H), 8.37 (d, J = 2.3, 1H), 8.00 (d, J =8.2, 1H), 7.71 (d, J = 7.7, 1H), 7.59-7.51 (m, 1H), 7.46 (dd, J = 7.3,15.1, 2H), 6.71 (d, J = 8.3, 1H), 6.67 (d, J = 7.4, 1H), 2.49 (s, 3H)¹³C NMR (75 MHz, CDCl₃) δ 157.13, 154.59, 145.81, 144.43, 138.78,134.54, 129.22, 128.86, 127.41, 127.27, 121.48, 115.41, 106.50, 24.18.MS (ESI) [M + H]⁺ = 236 14 MS (ESI) [M + H]⁺ = 266 15 MS (ESI) [M + H]⁺= 290 16 ¹H NMR (300 MHz, CDCl₃) δ 8.77 (dd, J = 1.5, 4.2, 1H), 8.04(dd, J = 4.7, 8.7, 2H), 7.92 (d, J = 2.4, 1H), 7.59 (dd, J = 2.5, 9.1,1H), 7.47 (t, J = 7.8, 1H), 7.35 (dd, J = 4.2, 8.3, 1H), 6.87 (s, 1H),6.81 (d, J = 8.2, 1H), 6.70 (d, J = 7.4, 1H), 2.50 (s, 3H) MS (ESI) [M +H]⁺ = 236 18 ¹H NMR (300 MHz, CDCl₃) δ 8.53 (d, J = 59.9, 2H), 7.76 (d,J = 8.6, 1H), 7.58 (t, J = 8.3, 2H), 7.42 (d, J = 7.8, 1H), 7.09 (t, J =7.7, 1H), 6.95 (d, J = 8.7, 1H), 6.71 (d, J = 7.3, 1H), 2.38 (s, 3H) 21¹H NMR (300 MHz, CDCl₃) δ 8.78 (s, 1H), 8.13 (d, J = 5.1, 1H), 7.89 (d,J = 8.3, 1H), 7.79 (s, 1H), 7.63 (d, J = 8.0, 1H), 7.56 (d, J = 7.3,1H), 7.38 (s, 1H), 7.33 (t, J = 7.5, 1H), 6.79 (d, J = 4.9, 1H), 2.44(s, 6H) 22 ¹H NMR (300 MHz, CDCl₃) δ 8.95 (d, J = 8.4, 1H), 8.28 (d, J =5.7, 1H), 7.87 (d, J = 8.3, 1H), 7.78 (s, 1H), 7.76-7.70 (m, 1H), 7.62(d, J = 8.0, 1H), 7.60-7.52 (m, 1H), 7.42 (s, 1H), 7.32 (t, J = 7.4,1H), 6.95 (dd, J = 5.1, 6.5, 1H), 2.45 (s, 3H) 23 ¹H NMR (300 MHz,CDCl₃) δ 8.64 (d, J = 8.4, 1H), 8.55 (d, J = 2.1, 1H), 8.03 (s, 1H),7.90 (d, J = 8.5, 4H), 7.66 (t, J = 7.6, 1H), 7.44 (t, J = 7.6, 1H),7.06 (s, 1H), 2.67 (s, 4H) 24 ¹H NMR (300 MHz, CDCl₃) δ 9.09 (d, J =8.9, 1H), 8.53 (d, J = 1.7, 1H), 7.94 (dd, J = 2.2, 8.9, 1H), 7.92-7.84(m, 2H), 7.67 (d, J = 8.6, 2H), 7.65-7.58 (m, 1H), 7.40 (t, J = 7.4,1H), 2.49 (s, 3H) 25 ¹H NMR (300 MHz, CDCl₃) δ 8.16 (d, J = 5.2, 1H),8.10 (s, 1H), 7.90 (d, J = 8.8, 1H), 7.79 (d, J = 9.0, 1H), 7.66 (d, J =2.2, 1H), 7.55 (dd, J = 2.3, 8.9, 1H), 7.39 (d, J = 9.0, 1H), 6.79 (d, J= 5.2, 1H), 2.42 (s, 3H) MS (ESI) [M + H]⁺ = 270 26 ¹H NMR (300 MHz,CDCl₃) δ 8.06 (d, J = 8.3, 1H), 7.70 (d, J = 9.0, 1H), 7.64 (d, J = 8.9,1H), 7.49 (t, J = 7.9, 2H), 7.40 (dd, J = 2.3, 8.9, 1H), 7.18 (d, J =8.9, 1H), 6.68 (d, J = 7.4, 1H), 2.38 (s, 3H) MS (ESI) [M + H]⁺ = 270 27¹H NMR (300 MHz, CDCl₃) δ 9.17 (d, J = 2.5, 1H), 8.71 (s, 1H), 8.49 (dd,J = 2.6, 9.0, 1H), 7.99 (s, 1H), 7.93 (d, J = 8.9, 2H), 7.74-7.64 (m,1H), 7.48 (dd, J = 4.2, 11.4, 1H), 7.09 (s, 1H), 2.71 (s, 3H) 28 ¹H NMR(300 MHz, CDCl₃) δ 8.64-8.51 (m, 3H), 8.18 (d, J = 9.0, 1H), 7.93 (d, J= 8.4, 1H), 7.79 (d, J = 8.1, 1H), 7.73-7.64 (m, 1H), 7.51-7.41 (m, 1H),7.00 (dd, J = 4.6, 8.2, 1H), 6.75 (dd, J = 4.6, 8.3, 0H) 29 ¹H NMR (300MHz, CDCl₃) δ 10.77 (s, 1H), 8.60 (s, 3H), 8.19 (d, J = 8.2, 1H), 7.76(dd, J = 6.6, 25.5, 2H), 7.38 (d, J = 7.2, 1H), 7.04 (d, J = 4.4, 1H) 30¹H NMR (300 MHz, CDCl₃) δ 8.46 (dd, J = 1.9, 5.0, 1H), 7.87 (dd, J =2.0, 7.6, 1H), 7.82 (d, J = 7.3, 1H), 7.60 (t, J = 7.3, 2H), 7.43-7.33(m, 1H), 6.90 (dd, J = 5.0, 7.6, 1H), 2.64 (s, 3H) 31 ¹H NMR (300 MHz,CDCl₃) δ 8.44 (d, J = 9.1, 1H), 8.17 (d, J = 4.8, 1H), 8.03 (d, J = 9.1,1H), 7.78 (d, J = 8.4, 1H), 7.68 (d, J = 8.0, 1H), 7.62-7.54 (m, 1H),7.39 (d, J = 7.3, 1H), 7.32 (t, J = 7.5, 1H), 6.82 (dd, J = 5.0, 7.3,1H), 2.31 (s, 3H) MS (ESI) [M + H]⁺ = 236 32 ¹H NMR (300 MHz, CDCl₃) δ8.23 (d, J = 8.5, 1H), 8.10 (s, 1H), 7.91 (d, J = 8.9, 1H), 7.82 (d, J =8.4, 1H), 7.62 (d, J = 8.3, 1H), 7.56 (d, J = 7.3, 1H), 7.50 (dd, J =1.8, 8.5, 1H), 7.37-7.24 (m, 2H), 2.26 (s, 3H) MS (ESI) [M + H]⁺ = 23633 ¹H NMR (300 MHz, CDCl₃) δ 8.87 (s, 1H), 8.32 (d, J = 5.0, 1H), 7.95(d, J = 8.8, 1H), 7.84 (d, J = 8.3, 1H), 7.60 (dd, J = 7.4, 14.1, 2H),7.32 (t, J = 7.5, 1H), 7.04 (dd, J = 5.0, 9.0, 2H) MS (ESI) [M + H]⁺ =247 34 ¹H NMR (300 MHz, CDCl₃) δ 8.52 (s, 1H), 8.45 (d, J = 8.6, 1H),8.01 (d, J = 8.8, 1H), 7.87 (dd, J = 2.5, 8.5, 2H), 7.72-7.56 (m, 2H),7.39 (d, J = 9.0, 2H) MS (ESI) [M + H]⁺ = 290 35 ¹H NMR (300 MHz, CDCl₃)δ 8.32 (d, J = 9.1, 1H), 8.07 (d, J = 4.8, 1H), 7.93 (d, J = 9.1, 1H),7.59 (t, J = 7.9, 1H), 7.52 (d, J = 8.0, 1H), 7.36 (d, J = 7.2, 1H),7.14 (t, J = 7.8, 1H), 6.77 (dd, J = 5.0, 7.3, 1H), 2.29 (s, 3H) MS(ESI) [M + H]⁺ = 270 36 ¹H NMR (300 MHz, CDCl₃) δ 8.70 (d, J = 7.2, 1H),8.01 (s, 1H), 7.82 (d, J = 8.9, 1H), 7.62 (d, J = 7.6, 1H), 7.53 (dd, J= 1.8, 8.6, 1H), 7.46 (d, J = 7.9, 1H), 7.12 (t, J = 7.8, 1H), 7.05 (d,J = 8.8, 1H), 2.21 (s, 3H) MS (ESI) [M + H]⁺ = 270 37 ¹H NMR (300 MHz,CDCl₃) δ 9.08 (d, J = 8.5, 1H), 8.55 (s, 1H), 8.36 (s, 1H), 8.02 (d, J =8.1, 2H), 7.77 (d, J = 7.2, 1H), 7.62 (d, J = 7.6, 1H), 7.35-7.24 (m,1H), 7.12 (d, J = 8.8, 1H) MS (ESI) [M + H]⁺ = 324 38 ¹H NMR (300 MHz,CDCl₃) δ 8.69 (d, J = 9.1, 1H), 7.97 (d, J = 9.1, 1H), 7.80-7.74 (m,1H), 7.70 (d, J = 8.4, 1H), 7.59 (d, J = 8.0, 1H), 7.54-7.45 (m, 1H),7.22 (t, J = 7.5, 1H), 6.87 (d, J = 7.9, 1H), 6.68 (dd, J = 5.0, 7.9,1H), 3.73 (s, 3H) MS (ESI) [M + H]⁺ = 252 39 ¹H NMR (300 MHz, CDCl₃) δ8.57 (d, J = 29.4, 1H), 7.80 (d, J = 8.8, 1H), 7.66 (t, J = 6.7, 2H),7.46 (d, J = 7.9, 1H), 7.14 (t, J = 7.8, 1H), 7.06 (d, J = 8.8, 1H),6.79 (d, J = 7.3, 1H), 2.73 (dd, J = 7.6, 15.2, 2H), 1.28 (t, J = 7.7,3H) 40 ¹H NMR (300 MHz, DMSO) δ 9.75 (s, 1H), 9.12 (d, J = 2.3, 1H),8.50 (d, J = 2.2, 1H), 8.48 (s, 1H), 8.13 (s, 1H), 7.83 (s, 1H), 7.80(s, 1H), 7.64 (t, J = 7.7, 1H), 7.45 (t, J = 7.8, 1H) 41 ¹H NMR (300MHz, CDCl₃) δ 8.52 (dd, J = 2.8, 8.6, 1H), 8.35 (s, 1H), 8.15 (d, J =2.3, 1H), 7.94 (d, J = 8.8, 1H), 7.84 (d, J = 8.2, 1H), 7.65 (d, J =7.8, 1H), 7.59 (d, J = 7.2, 1H), 7.50-7.40 (m, 1H), 7.33 (t, J = 7.4,1H), 7.11 (d, J = 8.9, 1H) MS (ESI) [M + H]⁺ = 240 42 ¹H NMR (300 MHz,CDCl₃) δ 8.55 (d, J = 6.8, 1H), 8.01 (d, J = 8.9, 2H), 7.82 (dd, J =9.1, 17.3, 2H), 7.69 (d, J = 8.0, 1H), 7.63 (t, J = 7.6, 1H), 7.37 (t, J= 7.5, 1H), 7.32-7.18 (m, 2H) MS (ESI) [M + H]⁺ = 290 43 ¹H NMR (300MHz, DMSO) δ 10.41 (s, 1H), 9.08 (dd, J = 4.1, 9.3, 1H), 8.31 (d, J =2.9, 1H), 8.20 (d, J = 8.9, 1H), 7.88-7.70 (m, 3H), 7.44 (d, J = 8.9,1H), 7.32 (t, J = 7.8, 1H) ¹³C NMR (75 MHz, DMSO) δ 156.30, 153.32,153.04, 150.17, 142.55, 137.73, 135.06, 134.74, 129.58, 129.49, 126.86,125.29, 125.14, 125.04, 123.36, 114.91, 113.36. MS (ESI) [M + H]⁺ = 27444 ¹H NMR (300 MHz, CDCl₃) δ 11.09 (s, 1H), 8.78 (d, J = 9.0, 1H), 8.42(dd, J = 1.9, 4.7, 1H), 8.28 (dd, J = 1.9, 7.8, 1H), 8.11 (d, J = 9.1,1H), 7.73 (d, J = 7.5, 1H), 7.65 (d, J = 8.1, 1H), 7.27 (dd, J = 6.4,9.2, 1H), 6.88 (dd, J = 4.8, 7.8, 1H) MS (ESI) [M + H]⁺ = 300 46 ¹H NMR(300 MHz, CDCl₃) δ 8.59 (d, J = 8.3, 1H), 7.73 (d, J = 8.3, 1H), 7.57(s, 1H), 7.51 (t, J = 7.9, 1H), 7.43 (t, J = 9.2, 2H), 7.17 (t, J = 7.4,1H), 6.67 (d, J = 7.4, 1H), 2.36 (s, 3H), 2.28 (s, 3H) 47 ¹H NMR (300MHz, MeOD) δ 8.99 (s, 1H), 8.76 (d, J = 9.2, 1H), 8.32 (d, J = 8.7, 1H),8.22 (d, J = 8.6, 1H), 8.11 (d, J = 7.8, 1H), 8.01 (t, J = 7.1, 1H),7.76 (t, J = 7.4, 1H), 7.55-7.43 (m, 2H) MS (ESI) [M + H]⁺ = 247 48 ¹HNMR (300 MHz, MeOD) δ 8.48 (d, J = 9.1, 1H), 8.40 (d, J = 6.7, 1H), 7.94(d, J = 8.4, 1H), 7.90 (d, J = 7.8, 1H), 7.54 (t, J = 8.0, 1H), 7.38 (d,J = 8.6, 1H), 7.30 (s, 2H), 2.58 (s, 3H) MS (ESI) [M + H]⁺ = 270 49 ¹HNMR (300 MHz, CDCl₃) δ 9.34 (s, 1H), 8.95 (s, 1H), 8.21 (d, J = 5.1,1H), 7.87 (d, J = 8.9, 1H), 7.71 (d, J = 7.5, 1H), 7.52 (d, J = 7.9,1H), 7.19 (t, J = 7.8, 1H), 7.05 (d, J = 8.9, 1H), 6.84 (d, J = 5.1,1H), 2.76 (q, J = 7.6, 2H), 1.37 (t, J = 7.6, 3H) 50 ¹H NMR (300 MHz,CDCl₃) δ 8.57 (d, J = 29.4, 1H), 7.80 (d, J = 8.8, 1H), 7.66 (t, J =6.7, 2H), 7.46 (d, J = 7.9, 1H), 7.14 (t, J = 7.8, 1H), 7.06 (d, J =8.8, 1H), 6.79 (d, J = 7.3, 1H), 2.73 (dd, J = 7.6, 15.2, 2H), 1.28 (t,J = 7.7, 3H) 51 ¹H NMR (300 MHz, CDCl₃) δ 8.64 (s, 1H), 8.06 (s, 1H),7.89 (d, J = 8.7, 1H), 7.71 (d, J = 7.4, 1H), 7.54 (d, J = 7.8, 1H),7.20 (t, J = 7.7, 1H), 7.02 (d, J = 8.8, 1H), 6.67 (s, 1H), 2.43 (s,3H), 2.39 (s, 3H) ¹³C NMR (75 MHz, CDCl₃) δ 156.15, 153.17, 152.82,150.16, 143.70, 137.92, 131.34, 129.89, 126.49, 125.47, 123.43, 118.62,114.47, 111.02, 24.13, 21.70. MS (ESI) [M + H]⁺ = 284 52 ¹H NMR (300MHz, CDCl₃) δ 8.89 (d, J = 8.8, 1H), 8.05 (d, J = 8.8, 1H), 8.01 (s,1H), 7.93 (d, J = 8.8, 1H), 7.79 (d, J = 7.5, 1H), 7.64 (d, J = 8.0,1H), 7.32 (t, J = 7.8, 1H), 7.13 (d, J = 8.8, 1H), 2.67 (s, 3H) 53 ¹HNMR (300 MHz, CDCl₃) δ 9.27 (s, 1H), 8.33 (d, J = 5.7, 1H), 8.13 (d, J =5.2, 1H), 8.00 (d, J = 8.8, 1H), 7.76 (d, J = 7.4, 1H), 7.60 (d, J =8.0, 1H), 7.29 (d, J = 7.9, 1H), 7.07 (d, J = 8.9, 1H), 6.97 (d, J =4.8, 1H) 54 MS (ESI) [M + H]⁺ = 250 55 ¹H NMR (300 MHz, CDCl₃) δ 8.19(s, 1H), 7.90 (d, J = 9.0, 1H), 7.63 (d, J = 7.5, 1H), 7.52 (d, J = 7.9,1H), 7.33 (d, J = 7.4, 1H), 7.14 (t, J = 7.8, 1H), 6.69 (d, J = 7.5,1H), 2.70 (dd, J = 7.3, 14.8, 2H), 2.47 (s, 3H), 1.26 (t, J = 7.7, 3H)56 ¹H NMR (300 MHz, CDCl₃) δ 8.20 (s, 1H), 7.90 (d, J = 9.0, 1H), 7.63(d, J = 7.5, 1H), 7.52 (d, J = 7.9, 1H), 7.33 (d, J = 7.4, 1H), 7.14 (t,J = 7.8, 1H), 6.69 (d, J = 7.5, 1H), 2.70 (dd, J = 7.3, 14.8, 2H), 2.47(s, 3H), 1.25 (dd, J = 7.5, 15.5, 3H) 57 MS (ESI) [M + H]⁺ = 253 58 MS(ESI) [M + H]⁺ = 314-316 59 ¹H NMR (300 MHz, CDCl₃) δ 8.91 (d, J = 1.7,1H), 8.46 (d, J = 8.8, 1H), 8.28 (dd, J = 2.0, 8.8, 1H), 8.23 (s, 1H),8.03 (d, J = 8.8, 1H), 7.88 (d, J = 8.3, 1H), 7.70 (d, J = 8.0, 1H),7.67-7.58 (m, 1H), 7.38 (t, J = 7.4, 1H), 7.32 (d, J = 8.8, 2H), 3.91(s, 3H) 60 ¹H NMR (300 MHz, CDCl₃) δ 8.94 (d, J = 8.9, 1H), 8.91 (d, J =1.8, 1H), 8.37 (dd, J = 2.2, 8.8, 1H), 8.04 (d, J = 8.9, 2H), 7.77 (d, J= 7.5, 1H), 7.62 (d, J = 7.2, 1H), 7.30 (t, J = 7.8, 2H), 7.19 (d, J =8.8, 2H), 3.92 (s, 3H) 61 ¹H NMR (300 MHz, CDCl₃) δ 8.96 (d, J = 8.8,1H), 8.85 (d, J = 1.3, 1H), 8.28 (d, J = 9.9, 1H), 7.84 (d, J = 8.0,1H), 7.77 (s, 1H), 7.65 (s, 1H), 7.59 (d, J = 8.4, 2H), 7.53 (d, J =8.4, 1H), 7.31 (t, J = 7.4, 1H), 3.88 (s, 4H), 2.42 (s, 4H) MS (ESI)[M + H]⁺ = 294 62 ¹H NMR (300 MHz, CDCl₃) δ 11.02 (s, 1H), 8.75 (d, J =9.2, 1H), 8.44 (d, J = 3.7, 1H), 8.31 (d, J = 7.9, 1H), 8.10 (d, J =9.0, 1H), 7.72 (d, J = 7.5, 1H), 7.64 (d, J = 8.2, 1H), 7.27 (d, J =8.1, 1H), 6.88 (dd, J = 4.7, 7.8, 1H), 3.97 (s, 3H) MS (ESI) [M + H]⁺ =314 63 MS (ESI) [M + H]⁺ = 266 64 ¹H NMR (300 MHz, DMSO) δ 10.38 (s,1H), 8.56 (s, 1H), 8.28 (d, J = 9.1, 1H), 8.20-8.03 (m, 3H), 7.50 (d, J= 8.7, 1H), 7.45 (d, J = 8.0, 1H), 6.88 (d, J = 4.4, 1H), 2.37 (s, 3H)65 MS (ESI) [M + H]⁺ = 314-316 66 MS (ESI) [M + H]⁺ = 250 67 ¹H NMR (300MHz, DMSO) δ 10.51 (s, 1H), 8.83 (d, J = 2.3, 1H), 8.62 (d, J = 9.3,1H), 8.24 (dd, J = 2.7, 9.1, 1H), 7.96 (d, J = 8.9, 1H), 7.81 (d, J =7.8, 1H), 7.67 (t, J = 7.6, 1H), 7.45 (d, J = 11.2, 2H), 3.86 (s, 3H),2.62 (s, 3H) MS (ESI) [M + H]⁺ = 294 68 ¹H NMR (300 MHz, CDCl₃) δ 9.57(s, 1H), 8.44 (d, J = 4.8, 1H), 8.05 (d, J = 8.8, 1H), 7.86 (s, 1H),7.80 (d, J = 7.5, 1H), 7.64 (d, J = 8.0, 1H), 7.31 (t, J = 7.8, 1H),7.19 (d, J = 4.3, 1H), 7.04 (d, J = 8.8, 1H) 69 ¹H NMR (300 MHz, CDCl₃)δ 9.12 (s, 1H), 7.94 (d, J = 8.6, 1H), 7.71 (d, J = 7.5, 1H), 7.57 (d, J= 7.8, 1H), 7.40 (s, 1H), 7.25 (d, J = 10.2, 2H), 7.17 (s, 1H), 7.05 (s,1H) 70 ¹H NMR (300 MHz, CDCl₃) δ 9.07 (d, J = 8.5, 1H), 7.97 (d, J =8.8, 1H), 7.90 (t, J = 8.0, 1H), 7.84 (s, 1H), 7.75 (dd, J = 1.1, 7.5,1H), 7.62-7.55 (m, 1H), 7.31 (d, J = 7.6, 1H), 7.27 (t, J = 7.8, 1H),7.08 (d, J = 8.8, 1H) MS (ESI) [M + H]⁺ = 274 71 MS (ESI) [M + H]⁺ = 27472 ¹H NMR (300 MHz, CDCl₃) δ 8.67 (d, J = 7.9, 1H), 7.83 (d, J = 8.3,1H), 7.71 (s, 1H), 7.69-7.61 (m, 1H), 7.57 (d, J = 7.9, 2H), 7.52 (d, J= 7.1, 1H), 7.28 (t, J = 7.4, 1H), 2.74 (q, J = 7.6, 2H), 2.42 (s, 3H),1.31 (t, J = 7.6, 3H) MS (ESI) [M + H]⁺ = 264 73 ¹H NMR (300 MHz, CDCl₃)δ 8.91 (dd, J = 3.8, 9.0, 1H), 8.11 (d, J = 2.9, 1H), 7.81 (d, J = 8.3,1H), 7.71 (s, 1H), 7.56 (dd, J = 7.4, 14.1, 2H), 7.51-7.42 (m, 1H), 7.29(d, J = 7.2, 1H), 2.38 (s, 3H) MS (ESI) [M + H]⁺ = 254 74 ¹H NMR (300MHz, CDCl₃) δ 8.96 (d, J = 8.3, 1H), 8.49 (s, 1H), 7.89 (dd, J = 1.9,9.0, 1H), 7.82 (d, J = 8.2, 1H), 7.72 (s, 1H), 7.57 (t, J = 8.7, 3H),7.33 (t, J = 7.4, 1H), 2.37 (s, 3H) MS (ESI) [M + H]⁺ = 304 75 ¹H NMR(300 MHz, CDCl₃) δ 7.83 (d, J = 9.0, 1H), 7.69 (dd, J = 1.3, 7.6, 1H),7.53 (dd, J = 1.2, 8.0, 1H), 7.42 (d, J = 8.9, 2H), 7.15 (t, J = 7.8,1H), 6.89 (d, J = 8.9, 2H), 6.79 (d, J = 8.9, 2H), 2.97 (s, 6H) 77 ¹HNMR (300 MHz, CDCl₃) δ 7.83 (d, J = 8.8, 1H), 7.70 (d, J = 7.6, 1H),7.59 (d, J = 8.6, 2H), 7.52 (d, J = 7.3, 1H), 7.16 (t, J = 7.7, 1H),6.94 (d, J = 8.4, 3H), 6.86 (d, J = 8.8, 1H), 3.82 (s, 3H) ¹³C NMR (75MHz, CDCl₃) δ 156.40, 155.54, 144.29, 138.09, 132.96, 130.44, 129.99,126.61, 125.22, 123.29, 122.66, 114.73, 112.16, 55.74. MS (ESI) [M + H]⁺= 285 78 ¹H NMR (300 MHz, CDCl₃) δ 7.80 (t, J = 7.6, 2H), 7.64 (d, J =8.9, 2H), 7.61- 7.55 (m, 1H), 7.33 (t, J = 7.6, 1H), 7.19 (d, J = 8.7,2H), 2.59 (s, 3H) 79 ¹H NMR (300 MHz, CDCl₃) δ 7.78 (d, J = 8.4, 1H),7.76-7.71 (m, 2H), 7.69 (s, 1H), 7.57 (dd, J = 1.1, 8.0, 1H), 7.51 (ddd,J = 1.5, 7.0, 8.4, 1H), 7.29-7.21 (m, 1H), 6.96-6.90 (m, 2H), 3.82 (s,3H), 2.35 (s, 3H) 80 ¹H NMR (300 MHz, CDCl₃) δ 7.92 (d, J = 8.9 Hz, 2H),7.84 (d, J = 8.3 Hz, 1H), 7.78 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.57(t, J = 7.7 Hz, 1H), 7.32 (t, J = 7.4 Hz, 1H), 7.24 (d, J = 8.7 Hz, 2H),6.53 (s, 1H), 2.42 (s, 3H) ¹³C NMR (75 MHz, CDCl₃) δ 152.46, 146.25,143.86, 139.33, 136.83, 128.93, 126.96, 126.71, 124.75, 123.56, 121.88,120.44, 119.95, 17.77. MS (ESI) [M + H]⁺ = 319 81 ¹H NMR (300 MHz,CDCl₃) δ 7.75 (d, J = 8.3, 1H), 7.66 (d, J = 8.5, 3H), 7.55 (d, J = 7.8,1H), 7.48 (t, J = 7.6, 1H), 7.20 (d, J = 7.2, 1H), 6.80 (d, J = 8.8,2H), 6.32 (s, 1H), 2.93 (s, 7H), 2.35 (s, 3H) 82 ¹H NMR (300 MHz, CDCl₃)δ 7.92 (d, J = 8.9, 1H), 7.82-7.70 (m, 2H), 7.66 (d, J = 7.8, 1H), 7.59(t, J = 7.6, 1H), 7.30 (dd, J = 6.0, 13.5, 1H), 7.14 (s, 1H), 7.11 (s,1H), 6.84 (d, J = 8.9, 1H), 2.32 (s, 3H) MS (ESI) [M + H]⁺ = 319 83 ¹HNMR (300 MHz, CDCl₃) δ 7.93-7.86 (m, 1H), 7.85 (s, 1H), 7.82 (d, J =8.4, 1H), 7.59 (dd, J = 8.2, 15.5, 2H), 7.44-7.38 (m, 1H), 7.29 (dd, J =8.3, 16.8, 2H), 6.91 (d, J = 9.0, 1H), 6.87 (d, J = 8.3, 1H) MS (ESI)[M + H]⁺ = 305 84 ¹H NMR (300 MHz, CDCl₃) δ 8.67 (d, J = 8.1, 1H), 7.92(d, J = 8.9, 1H), 7.85 (d, J = 8.4, 1H), 7.63 (d, J = 7.6, 1H), 7.58 (d,J = 7.3, 1H), 7.30 (dd, J = 6.8, 14.8, 3H), 7.02 (t, J = 7.8, 1H), 6.89(d, J = 8.9, 1H) MS (ESI) [M + H]⁺ = 305 86 ¹H NMR (300 MHz, CDCl₃) δ7.93 (d, J = 8.9, 1H), 7.83 (d, J = 8.3, 1H), 7.70 (d, J = 12.0, 1H),7.61 (dd, J = 7.9, 18.1, 2H), 7.32 (d, J = 7.9, 1H), 7.31-7.25 (m, 1H),7.21 (t, J = 6.5, 1H), 6.92 (d, J = 8.9, 1H), 6.79-6.68 (m, 1H) MS (ESI)[M + H]⁺ = 239 87 ¹H NMR (300 MHz, CDCl₃) δ 8.27 (s, 1H), 7.76 (d, J =8.9, 1H), 7.67 (d, J = 7.5, 1H), 7.51 (d, J = 8.2, 1H), 7.45 (d, J =7.9, 1H), 7.28 (d, J = 8.2, 1H), 7.14 (t, J = 7.8, 1H), 6.86 (d, J =10.1, 1H), 6.76 (d, J = 8.9, 1H) MS (ESI) [M + H]⁺ = 339 88 ¹H NMR (300MHz, CDCl₃) δ 8.11 (dt, J = 2.1, 12.1, 1H), 7.76 (d, J = 8.9, 1H), 7.66(dd, J = 1.2, 7.6, 1H), 7.45 (dd, J = 1.1, 8.0, 1H), 7.22 (dd, J = 1.4,7.2, 2H), 7.18 (d, J = 7.6, 1H), 7.12 (d, J = 7.8, 1H), 6.75 (d, J =8.9, 1H), 6.69 (d, J = 7.9, 1H) MS (ESI) [M + H]⁺ = 273 89 ¹H NMR (300MHz, DMSO) δ 11.38 (s, 1H), 8.41 (d, J = 9.1, 1H), 7.93 (d, J = 7.8,1H), 7.80 (dt, J = 8.1, 20.9, 4H), 7.50 (d, J = 7.8, 3H), 7.36 (d, J =9.3, 1H) 90 ¹H NMR (300 MHz, CDCl₃) δ 7.84 (d, J = 9.1, 2H), 7.79 (d, J= 8.9, 1H), 7.67 (dd, J = 1.2, 7.6, 1H), 7.48 (dd, J = 1.1, 8.0, 1H),7.18 (s, 3H), 6.89 (s, 1H), 6.75 (d, J = 8.9, 1H) ¹³C NMR (75 MHz,CDCl₃) δ 153.88, 144.30, 143.91, 139.00, 138.25, 131.13, 130.13, 126.55,125.42, 123.45, 122.50, 122.17, 120.49, 119.10, 113.24. MS (ESI) [M +H]⁺ = 339 91 ¹H NMR (300 MHz, CDCl₃) δ 8.74 (s, 1H), 8.54 (s, 1H), 8.46(d, J = 8.8, 1H), 7.91 (dd, J = 5.5, 14.5, 2H), 7.79 (d, J = 8.9, 1H),7.67 (d, J = 2.1, 1H), 7.56 (dd, J = 2.3, 8.9, 1H), 7.35 (d, J = 8.9,1H) 92 ¹H NMR (300 MHz, CDCl₃) δ 8.67 (d, J = 7.9, 1H), 7.83 (d, J =8.3, 1H), 7.71 (s, 1H), 7.69-7.61 (m, 1H), 7.55 (dd, J = 7.5, 14.4, 2H),7.29 (d, J = 7.8, 1H), 6.80 (d, J = 7.4, 1H) 93 ¹H NMR (300 MHz, CDCl₃)δ 9.21 (dd, J = 1.5, 8.4, 1H), 7.85 (d, J = 8.4, 1H), 7.73 (s, 1H), 7.58(d, J = 7.8, 1H), 7.53 (dd, J = 1.3, 8.3, 1H), 7.40-7.35 (m, 1H), 7.32(dd, J = 1.1, 4.6, 1H), 7.31-7.24 (m, 2H), 7.04 (s, 1H), 7.02-6.94 (m,1H), 2.38 (s, 3H) 94 ¹H NMR (300 MHz, CDCl₃) δ 8.16 (d, J = 8.7, 1H),7.83 (d, J = 8.9, 1H), 7.63 (d, J = 7.6, 1H), 7.48 (d, J = 8.0, 1H),7.13 (t, J = 7.8, 1H), 7.08 (s, 1H), 7.04 (s, 2H), 6.81 (d, J = 8.9,2H), 2.27 (s, 3H) MS (ESI) [M + H]⁺ = 353 95 ¹H NMR (300 MHz, MeOD) δ8.42 (s, 1H), 7.94 (d, J = 7.9, 1H), 7.83 (d, J = 8.1, 1H), 7.78 (d, J =7.1, 1H), 7.72 (d, J = 8.7, 2H), 7.58 (d, J = 8.2, 3H), 2.60 (s, 3H) MS(ESI) [M + H]⁺ = 319 96 ¹H NMR (300 MHz, CDCl₃) δ 7.79 (d, J = 8.9, 1H),7.70 (d, J = 8.9, 1H), 7.64 (d, J = 8.9, 2H), 7.59 (d, J = 2.1, 1H),7.50 (dd, J = 2.3, 8.9, 1H), 7.19 (d, J = 8.6, 2H), 6.85 (d, J = 8.9,1H) MS (ESI) [M + H]⁺ = 281 97 ¹H NMR (300 MHz, MeOD) δ 8.11 (d, J =8.4, 1H), 7.81 (s, 2H), 7.62 (d, J = 8.7, 3H), 7.51 (d, J = 8.3, 2H),7.12 (s, 1H), 2.77 (s, 3H) MS (ESI) [M + H]⁺ = 319 98 MS (ESI) [M + H]⁺= 383-385 99 MS (ESI) [M + H]⁺ = 320 100 MS (ESI) [M + H]⁺ = 316 101 ¹HNMR (300 MHz, CDCl₃) δ 7.82 (d, J = 8.9, 1H), 7.70-7.63 (m, 1H), 7.51(dd, J = 5.3, 7.6, 3H), 7.14 (t, J = 7.8, 1H), 6.91 (d, J = 8.8, 3H),6.85 (d, J = 9.0, 2H), 3.96 (t, J = 6.5, 2H), 1.84-1.68 (m, 3H), 1.49(dd, J = 7.4, 15.0, 3H), 0.97 (t, J = 7.4, 3H) MS (ESI) [M + H]⁺ = 327102 ¹H NMR (300 MHz, CDCl₃) δ 7.89 (d, J = 8.9, 1H), 7.76 (d, J = 8.5,1H), 7.63 (d, J = 8.1, 1H), 7.59 (s, 1H), 7.54 (d, J = 8.8, 2H),7.38-7.24 (m, 3H), 7.09 (d, J = 7.4, 1H), 7.02 (dd, J = 2.4, 8.8, 4H),6.90 (d, J = 8.9, 1H) MS (ESI) [M + H]⁺ = 313 103 MS (ESI) [M + H]⁺ =334 104 ¹H NMR (300 MHz, CDCl₃) δ 8.49 (d, J = 2.5, 1H), 7.89 (d, J =8.8, 1H), 7.72 (d, J = 7.6, 1H), 7.63 (dd, J = 2.5, 8.9, 1H), 7.53 (d, J= 8.0, 1H), 7.23 (dd, J = 6.2, 14.0, 2H), 7.04 (s, 1H), 6.81 (d, J =8.8, 1H) MS (ESI) [M + H]⁺ = 373 105 ¹H NMR (300 MHz, CDCl₃) δ 8.85 (d,J = 2.6, 1H), 8.45 (d, J = 2.3, 1H), 8.01 (d, J = 8.1, 1H), 7.71 (d, J =7.8, 1H), 7.58 (s, 1H), 7.53 (d, J = 7.6, 1H), 7.51-7.45 (m, 2H),7.45-7.36 (m, 1H), 6.72-6.62 (m, 2H), 2.48 (s, 3H) 13C NMR (75 MHz,CDCl₃) δ 157.18, 154.80, 145.42, 143.80, 138.17, 135.04, 128.88, 128.76,127.17, 127.04, 120.69, 115.22, 106.73, 24.38 106 ¹H NMR (300 MHz, DMSO)δ 10.24 (s, 1H), 9.06 (d, J = 2.3, 1H), 8.65 (d, J = 1.8, 1H), 8.60 (d,J = 8.3, 1H), 8.56 (d, J = 4.5, 1H), 7.97 (dd, J = 8.2, 14.4, 2H), 7.69(t, J = 6.9, 1H), 7.59 (t, J = 7.4, 1H), 7.08 (dd, J = 4.6, 8.3, 1H) MS(ESI) [M + H]⁺ = 267 107 ¹H NMR (300 MHz, CDCl₃) δ 8.77 (dd, J = 1.5,4.3, 1H), 8.06 (dd, J = 10.8, 18.4, 3H), 7.93 (d, J = 2.4, 1H), 7.57(dd, J = 2.4, 9.0, 1H), 7.39 (ddd, J = 3.1, 8.3, 12.5, 3H), 6.93 (d, J =8.4, 1H), 6.89 (s, 1H), 2.29 (s, 3H) 108 ¹H NMR (300 MHz, CDCl₃) δ 8.72(dd, J = 1.6, 4.2, 1H), 8.61 (d, J = 2.4, 1H), 8.11 (d, J = 8.3, 1H),8.00 (d, J = 9.0, 1H), 7.91 (dd, J = 1.2, 5.0, 1H), 7.69 (dd, J = 2.4,9.1, 1H), 7.35-7.26 (m, 2H), 7.01 (dd, J = 1.2, 7.9, 1H), 6.77 (dd, J =5.1, 7.8, 1H), 3.93 (s, 3H) 109 ¹H NMR (300 MHz, CDCl₃) δ 9.68 (s, 1H),8.21 (s, 2H), 7.94 (d, J = 8.9, 1H), 7.79 (d, J = 9.2, 1H), 7.67 (d, J =2.3, 1H), 7.56 (dd, J = 2.3, 8.9, 1H), 7.34 (d, J = 8.9, 1H) MS (ESI)[M + H]⁺ = 257 110 1H NMR (300 MHz, CDCl₃) δ 10.32 (s, 1H), 8.33-8.21(m, 2H), 8.05 (d, J = 8.9, 1H), 8.00 (dd, J = 1.2, 7.6, 1H), 7.69 (dd, J= 1.1, 7.8, 1H), 7.61 (s, 1H), 7.30- 7.22 (m, 3H), 7.16 (d, J = 8.8,1H). MS (ESI) [M + H]⁺ = 301-303 111 ¹H NMR (300 MHz, CDCl₃) δ 7.82 (d,J = 8.9, 1H), 7.70-7.63 (m, 1H), 7.51 (dd, J = 5.3, 7.6, 3H), 7.14 (t, J= 7.8, 1H), 6.91 (d, J = 8.8, 3H), 6.85 (d, J = 9.0, 2H), 3.96 (t, J =6.5, 2H), 1.84-1.68 (m, 3H), 1.49 (dd, J = 7.4, 15.0, 3H), 0.97 (t, J =7.4, 3H) 112 ¹H NMR (300 MHz, CDCl₃) δ 7.89 (d, J = 8.9, 1H), 7.76 (d, J= 8.5, 1H), 7.63 (d, J = 8.1, 1H), 7.59 (s, 1H), 7.54 (d, J = 8.8, 2H),7.38-7.24 (m, 3H), 7.09 (d, J = 7.4, 1H), 7.02 (dd, J = 2.4, 8.8, 4H),6.90 (d, J = 8.9, 1H) ¹³C NMR (75 MHz, DMSO) δ 152.94, 150.19, 142.48,142.18, 138.20, 137.55, 135.74, 129.71, 126.99, 125.35, 123.84, 114.75.MS (ESI) [M + H]⁺ = 255 113 ¹H NMR (300 MHz, CDCl₃) δ 9.74 (s, 1H), 8.20(s, 2H), 8.03 (d, J = 8.6, 1H), 7.87 (d, J = 7.6, 1H), 7.80 (s, 1H),7.70 (d, J = 8.0, 1H), 7.63 (t, J = 7.7, 1H), 7.37 (t, J = 7.4, 1H),7.30 (d, J = 8.7, 1H) 114 ¹H NMR (300 MHz, CDCl₃) δ 9.67 (s, 1H),8.34-8.12 (m, 2H), 7.84 (d, J = 8.0, 2H), 7.70-7.54 (m, 1H), 7.38 (t, J= 7.6, 1H), 7.17 (s, 1H), 2.61 (s, 3H) MS (ESI) [M + H]⁺ = 237 115 ¹HNMR (300 MHz, CDCl₃) δ 10.15 (s, 1H), 8.24-8.12 (m, 2H), 7.79 (s, 1H),7.71 (s, 1H), 7.55 (t, J = 8.3, 2H), 7.30 (t, J = 7.9, 1H), 2.38 (s, 3H)MS (ESI) [M + H]⁺ = 237 116 MS (ESI) [M + H]⁺ = 240 117 MS (ESI) [M +H]⁺ = 253 118 MS (ESI) [M + H]⁺ = 222 119 MS (ESI) [M + H]⁺ = 256 121 MS(ESI) [M + H]⁺ = 222 124 ¹H NMR (300 MHz, CDCl₃) δ 8.42 (s, 1H), 7.95(dd, J = 1.3, 8.2, 1H), 7.87-7.78 (m, 3H), 7.70-7.61 (m, 1H), 7.55-7.47(m, 1H), 7.26 (dd, J = 2.4, 6.5, 3H), 6.90 (s, 1H) MS (ESI) [M + H]⁺ =306 125 ¹H NMR (300 MHz, CDCl₃) δ 8.42 (s, 1H), 8.03 (d, J = 9.5, 1H),7.92 (d, J = 8.2, 1H), 7.73 (d, J = 8.2, 1H), 7.61 (t, J = 7.3, 1H),7.46 (t, J = 7.2, 1H), 7.13 (s, 2H), 6.84 (s, 1H), 2.35 (s, 3H) 126 ¹HNMR (300 MHz, CDCl₃) δ 8.40 (s, 1H), 8.03 (s, 1H), 7.94 (d, J = 8.2,1H), 7.84 (d, J = 8.2, 1H), 7.65 (t, J = 7.4, 1H), 7.53 (d, J = 7.1,1H), 7.48 (d, J = 7.2, 1H), 7.35 (t, J = 8.2, 1H), 7.22 (s, 1H), 6.94(d, J = 8.1, 1H) 127 ¹H NMR (300 MHz, CDCl₃) δ 8.85 (dd, J = 1.0, 8.3,1H), 8.47 (s, 1H), 7.96 (d, J = 8.2, 1H), 7.85 (d, J = 8.3, 1H),7.72-7.61 (m, 1H), 7.57-7.47 (m, 1H), 7.42- 7.36 (m, 1H), 7.33 (d, J =10.0, 1H), 7.14 (s, 1H), 7.13-7.04 (m, 1H) 128 ¹H NMR (300 MHz, CDCl₃) δ9.17 (s, 1H), 8.68 (d, J = 9.1, 1H), 8.64 (d, J = 4.8, 2H), 8.15 (d, J =9.1, 1H), 7.87 (d, J = 8.4, 1H), 7.76 (d, J = 8.1, 1H), 7.64 (t, J =7.7, 1H), 7.39 (t, J = 7.5, 1H), 6.87 (t, J = 4.8, 1H) ¹³C NMR (75 MHz,CDCl3) δ 158.34, 138.07, 129.85, 127.63, 127.31, 124.34, 114.20, 113.90.129 ¹H NMR (300 MHz, CDCl₃) δ 9.14 (s, 1H), 8.73 (d, J = 21.2, 3H), 8.17(s, 1H), 7.73 (d, J = 20.3, 2H), 7.28 (d, J = 9.6, 2H), 6.91 (s, 1H) 130¹H NMR (300 MHz, CDCl₃) δ 9.05 (s, 1H), 8.64 (d, J = 4.8, 2H), 8.52 (s,1H), 7.89 (dd, J = 8.5, 14.6, 2H), 7.63 (t, J = 7.5, 1H), 7.41 (t, J =7.4, 1H), 6.86 (t, J = 4.8, 1H), 2.74 (s, 3H) MS (ESI) [M + H]⁺ = 237132 ¹H NMR (300 MHz, CDCl₃) δ 8.86 (d, J = 2.6, 1H), 8.70 (d, J = 2.5,1H), 8.32 (d, J = 1.1, 1H), 8.25-8.21 (m, 1H), 8.10 (d, J = 2.7, 1H),8.06 (d, J = 8.3, 1H), 7.82 (dd, J = 1.2, 7.9, 1H), 7.66-7.51 (m, 3H),6.89 (s, 1H) 135 ¹H NMR (300 MHz, CDCl₃) δ 9.09 (s, 1H), 8.71 (s, 1H),8.54 (d, J = 8.4, 1H), 8.37 (dd, J = 1.0, 4.9, 1H), 7.96 (d, J = 8.2,1H), 7.85 (d, J = 8.3, 1H), 7.82-7.74 (m, 1H), 7.66 (t, J = 7.6, 1H),7.52 (dd, J = 7.0, 8.1, 1H), 7.02 (dd, J = 5.0, 7.2, 1H) MS (ESI) [M +H]⁺ = 223 136 ¹H NMR (300 MHz, CDCl₃) δ 9.02 (s, 1H), 8.70 (s, 1H), 8.30(s, 1H), 8.20 (d, J = 5.1, 1H), 7.94 (d, J = 8.1, 1H), 7.84 (d, J = 8.2,1H), 7.64 (t, J = 7.6, 1H), 7.49 (t, J = 8.1, 1H), 6.83 (d, J = 5.0,1H), 2.43 (s, 3H) ¹³C NMR (75 MHz, CDCl₃) δ 153.28, 150.20, 148.55,147.40, 140.93, 139.83, 138.35, 130.44, 129.16, 127.18, 126.28, 119.70,113.75, 21.87. MS (ESI) [M + H]⁺ = 237 137 ¹H NMR (300 MHz, DMSO) δ11.10 (s, 1H), 9.03 (s, 1H), 8.82-8.75 (m, 1H), 8.56 (d, J = 8.9, 1H),8.24 (dd, J = 2.3, 8.9, 1H), 7.96 (dd, J = 1.2, 8.2, 1H), 7.87 (dd, J =1.0, 8.3, 1H), 7.79-7.71 (m, 1H), 7.61 (ddd, J = 1.4, 7.0, 8.3, 1H) MS(ESI) [M + H]⁺ = 248 138 ¹H NMR (300 MHz, CDCl₃) δ 8.72 (s, 1H), 8.53(s, 1H), 8.20 (d, J = 8.3, 1H), 7.93 (d, J = 8.2, 1H), 7.81 (d, J = 8.3,1H), 7.62 (td, J = 3.4, 8.1, 2H), 7.53-7.43 (m, 1H), 6.83 (d, J = 7.4,1H), 2.48 (s, 3H) ¹³C NMR (75 MHz, CDCl₃) δ 156.86, 152.27, 148.40,140.92, 139.70, 139.00, 138.35, 130.42, 129.13, 127.14, 126.27, 117.76,110.01, 24.15. MS (ESI) [M + H]⁺ = 237 139 ¹H NMR (300 MHz, CDCl₃) δ8.53 (s, 1H), 8.20 (d, J = 4.8, 1H), 8.04 (d, J = 8.3, 1H), 7.92 (d, J =8.4, 1H), 7.87 (s, 1H), 7.79 (t, J = 7.6, 1H), 7.60 (t, J = 7.6, 1H),6.88 (d, J = 4.7, 1H), 2.46 (s, 3H) 140 ¹H NMR (300 MHz, CDCl₃) δ 9.93(s, 1H), 8.19 (s, 1H), 8.05 (d, J = 8.1, 1H), 7.99 (s, 1H), 7.82 (d, J =8.2, 1H), 7.69 (t, J = 7.6, 1H), 7.59 (t, J = 8.2, 1H), 2.53 (s, 4H) 141¹H NMR (300 MHz, CDCl₃) δ 9.72 (s, 1H), 9.35 (s, 1H), 8.30 (d, J = 5.0,1H), 8.05 (d, J = 7.7, 1H), 7.87 (d, J = 7.0, 1H), 7.66 (dd, J = 7.4,16.9, 3H), 6.92 (d, J = 4.9, 1H), 2.58 (s, 3H) 143 ¹H NMR (300 MHz,DMSO) δ 8.85 (s, 1H), 8.42 (d, J = 5.3, 1H), 7.96 (d, J = 9.1, 1H), 7.44(s, 1H), 7.30 (s, 4H), 7.28-7.21 (m, 2H), 6.66 (d, J = 5.3, 1H), 2.99(s, 6H) ¹³C NMR (75 MHz, DMSO) δ 156.82, 150.25, 149.69, 143.79, 141.71,125.95, 122.33, 118.88, 117.37, 115.95, 109.39, 104.92, 43.57 MS (ESI)[M + H]+ = 348 144 MS (ESI) [M + H]⁺ = 390 145 MS (ESI) [M + H]⁺ = 252146 ¹H NMR (300 MHz, DMSO) δ 9.34 (s, 1H), 8.59 (d, J = 5.2, 1H), 8.53(s, 1H), 8.13 (d, J = 5.1, 1H), 7.98 (d, J = 9.0, 1H), 7.66 (d, J = 9.1,1H), 6.80 (d, J = 5.2, 1H), 6.76 (s, 1H), 6.69 (d, J = 4.9, 1H), 4.00(s, 3H), 2.26 (s, 3H) ¹³C NMR (75 MHz, DMSO) δ 161.31, 155.67, 151.63,150.25, 147.77, 147.01, 142.97, 121.56, 119.16, 116.61, 114.75, 112.60,111.41, 98.91, 55.78, 20.66. MS (ESI) [M + H]⁺ = 266 147 MS (ESI) [M +H]⁺ = 279 149 MS (ESI) [M + H]⁺ = 318 150 MS (ESI) [M + H]⁺ = 280 151 ¹HNMR (300 MHz, CDCl₃) δ 8.35 (s, 1H), 8.04 (d, J = 8.3, 1H), 7.82 (d, J =8.9, 1H), 7.74 (d, J = 8.9, 1H), 7.60 (t, J = 7.8, 2H), 7.50 (dd, J =2.3, 8.9, 1H), 7.36 (d, J = 8.9, 1H), 6.79 (d, J = 7.4, 1H), 2.75 (q, J= 7.6, 2H), 1.30 (t, J = 7.6, 3H). MS (ESI) [M + H]⁺ = 284 152 ¹H NMR(300 MHz, CDCl₃) δ 8.30 (d, J = 8.5, 1H), 8.08 (s, 1H), 7.90 (d, J =9.0, 1H), 7.77 (d, J = 8.9, 1H), 7.65 (d, J = 2.2, 1H), 7.55 (td, J =2.0, 8.8, 2H), 7.39 (d, J = 9.0, 1H), 2.31 (s, 3H). MS (ESI) [M + H]⁺ =270 153 ¹H NMR (300 MHz, CDCl₃) δ 8.75 (s, 1H), 8.54 (s, 1H), 8.46 (d, J= 8.8, 1H), 7.91 (dd, J = 5.5, 14.5, 2H), 7.79 (d, J = 8.9, 1H), 7.67(d, J = 2.1, 1H), 7.56 (dd, J = 2.3, 8.9, 1H), 7.35 (d, J = 8.9, 1H). MS(ESI) [M + H]⁺ = 324 154 ¹H NMR (300 MHz, DMSO) δ 9.08 (s, 1H), 8.12 (d,J = 8.4, 1H), 7.73 (d, J = 8.2, 2H), 7.66 (d, J = 10.0, 1H), 7.53 (s,1H), 7.25 (s, 1H), 6.82 (s, 1H), 5.10 (s, 2H), 2.16 (s, 4H). MS (ESI)[M + H]⁺ = 285 155 ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J = 8.3, 1H), 7.61(s, 1H), 7.56 (d, J = 11.5, 2H), 7.44 (d, J = 8.3, 1H), 7.38 (d, J =7.8, 1H), 7.13 (t, J = 7.4, 1H), 6.80 (d, J = 8.7, 2H), 3.85 (t, J =6.5, 2H), 2.18 (s, 3H), 1.73-1.58 (m, 2H), 1.48-1.31 (m, 2H), 0.88 (t, J= 7.3, 3H) MS (ESI) [M + H]⁺ = 307 156 ¹H NMR (300 MHz, CDCl₃) δ 7.75(d, J = 9.1, 1H), 7.62 (d, J = 8.9, 1H), 7.58 (d, J = 2.2, 1H), 7.48(dd, J = 2.4, 8.9, 1H), 7.30 (d, J = 8.9, 2H), 6.86 (d, J = 9.0, 1H),6.77 (d, J = 8.9, 2H), 6.71 (s, 1H), 2.97 (s, 6H) MS (ESI) [M + H]⁺ =298 157 ¹H NMR (300 MHz, CDCl₃) δ 7.98 (d, J = 2.6, 1H), 7.89 (d, J =8.9, 1H), 7.72 (d, J = 7.5, 1H), 7.62 (dd, J = 2.6, 8.8, 1H), 7.55 (d, J= 7.8, 1H), 7.20 (t, J = 7.8, 1H), 6.95 (d, J = 8.9, 1H), 6.84 (d, J =8.9, 1H), 6.79 (s, 1H), 3.91 (s, 3H) MS (ESI) [M + H]⁺ = 319 158 ¹H NMR(300 MHz, CDCl₃) δ 7.89 (d, J = 9.0, 1H), 7.70 (dd, J = 1.2, 7.5, 1H),7.56 (dd, J = 1.1, 8.0, 1H), 7.30 (d, J = 8.6, 1H), 7.20 (t, J = 7.8,1H), 6.71 (t, J = 5.9, 2H), 6.64 (d, J = 9.5, 1H). MS (ESI) [M + H]⁺ =354 159 ¹H NMR (300 MHz, CDCl₃) δ 8.80 (d, J = 2.6, 1H), 8.37 (d, J =2.6, 1H), 8.01 (d, J = 8.1, 1H), 7.91 (dd, J = 1.6, 4.9, 1H), 7.78-7.70(m, 1H), 7.58-7.43 (m, 2H), 7.09 (dd, J = 1.6, 7.6, 1H), 6.84 (dd, J =4.9, 7.6, 1H), 6.69 (s, 1H), 3.82-3.07 (m, 2H). 160 ¹H NMR (300 MHz,CDCl₃) δ 9.68-8.90 (m, 1H), 8.77 (s, 1H), 8.35 (s, 1H), 8.14 (d, J =5.0, 1H), 7.96 (s, 1H), 7.79 (d, J = 8.8, 1H), 7.61 (d, J = 8.5, 1H),6.88 (d, J = 4.8, 1H), 2.46 (s, 3H) 161 ¹H NMR (300 MHz, CDCl₃) δ 9.98(s, 1H), 8.70 (s, 1H), 8.45 (s, 1H), 8.27 (d, J = 5.2, 1H), 7.94 (d, J =8.1, 1H), 7.84 (d, J = 8.2, 1H), 7.63 (t, J = 7.5, 1H), 7.48 (t, J =7.5, 1H), 6.87 (d, J = 5.0, 1H), 2.74 (q, J = 7.6, 2H), 1.34 (t, J =7.6, 3H). MS (ESI) [M + H]⁺ = 251 162 ¹H NMR (300 MHz, CDCl₃) δ 8.73 (s,1H), 8.70-8.60 (m, 1H), 8.48 (s, 1H), 8.31 (s, 1H), 7.98 (d, J = 8.1,1H), 7.86 (d, J = 7.9, 1H), 7.68 (t, J = 8.2, 1H), 7.54 (t, J = 8.1,1H), 2.49 (s, 3H) MS (ESI) [M + H]⁺ = 315 163 ¹H NMR (300 MHz, CDCl₃) δ8.75 (s, 1H), 8.68 (s, 1H), 8.01 (s, 1H), 7.95 (d, J = 8.2, 1H), 7.84(d, J = 8.3, 1H), 7.64 (t, J = 8.2, 1H), 7.49 (t, J = 7.0, 1H), 6.69 (s,1H), 2.45 (s, 3H), 2.38 (s, 3H) MS (ESI) [M + H]⁺ = 251 164 ¹H NMR (300MHz, DMSO) δ 10.46 (s, 1H), 9.00 (s, 1H), 8.41 (s, 1H), 8.24 (d, J =3.0, 1H), 7.90 (d, J = 8.2, 1H), 7.79 (d, J = 8.3, 1H), 7.69 (t, J =7.0, 1H), 7.52 (t, J = 7.4, 1H), 6.98 (d, J = 4.8, 1H), 5.45 (q, J =5.6, 1H), 4.58 (d, J = 5.7, 2H). MS (ESI) [M + H]⁺ = 253 165 ¹H NMR (300MHz, CDCl₃) δ 9.07 (s, 1H), 8.79 (s, 1H), 8.51 (s, 1H), 8.18 (s, 1H),8.09-8.01 (m, 1H), 7.94 (d, J = 8.4, 1H), 7.81-7.71 (m, 1H), 7.69-7.59(m, 1H), 2.80 (s, 3H) MS (ESI) [M + H]⁺ = 282 166 ¹H NMR (300 MHz,CDCl₃) δ 8.49 (d, J = 5.0, 1H), 7.77 (d, J = 9.0, 1H), 7.32 (d, J = 2.0,1H), 7.12 (d, J = 9.0, 2H), 6.99 (dd, J = 2.0, J = 9.0, 1H), 6.82 (d, J= 9.0, 2H), 6.57 (d, J = 5.0, 1H), 5.78 (s, 1H), 3.74 (s, 3H), 3.17 (s,4H), 2.62 (s, 4H), 2.34 (s, 3H) 167 MS (ESI) [M + H]⁺ = 335 168 MS (ESI)[M + H]⁺ = 321

The following examples illustrate in detail the preparation of compounds(51), (64), (110), (143) and (148) as described above. The structures ofthe products obtained have been confirmed at least by NMR spectra.

EXAMPLES

According to route (A), the compound of formula (III) is placed in aprotic solvent such as tert-butanol. The compound of formula (IV) isthen added in a 1.1 molar ratio with respect to the compound of formula(III) in presence of an inorganic base, such as Cs₂CO₃ or K₂CO₃, in a2.8 molar ratio, in the presence of a diphosphine, such as Xantphos(4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene), or X-Phos2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl in a 2 mol %amount relative to the total amount of compound of formula (III), and inthe presence of a catalyst, such as Pd(OAc)₂ or Pd₂dba₃ in a 2 mol %amount relative to the total amount of compound of formula (III). Thereaction mixture is then heated at 90° C., and stirred during 20 hours,under argon. The reaction mixture is concentrated under reduced pressureand the resulting residue is diluted with ethyl acetate. The organicphase is then washed twice with water, dried on magnesium sulphate,filtered and concentrated under reduced pressure. The residue could thenbe purified by column chromatography on silica gel to yield purecompounds (51), (64), (110), and (143).

According to route (B), the compound of formula (V) is placed in aprotic solvent such as tert-butanol. The compound of formula (VI) isthen added in a 1.1 molar ratio with respect to the compound of formula(V) in presence of Cs₂CO₃ in a 2.8 molar ratio, in the presence ofXantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) in a 2 mol %amount relative to the total amount of compound of formula (V), and inthe presence of a Pd(OAc)₂, in a 2 mol % amount relative to the totalamount of compound of formula (V). The reaction mixture is then heatedat 90° C., and stirred during 20 hours, under argon. The reactionmixture is concentrated under reduced pressure and the resulting residueis diluted with ethyl acetate. The organic phase is then washed twicewith water, dried on magnesium sulphate, filtered and concentrated underreduced pressure. The residue could then be purified by columnchromatography on silica gel to yield pure compound (148).

Example 1 Compound (51) of Table I

According to route (A), a mixture of 2,8-dichloroquinoline (98.5 mg) and2-amino-4,6-dimethylpyridine (67.1 mg), Pd(OAc)₂ (2.2 mg), XantPhos (5.8mg) and Cs₂CO₃ (456 mg) in 2 mL of t-BuOH gave compound (51) (99.7 mg).

Example 2 Compound (64) of Table I

According to route (A), a mixture of 2-chloro-5-nitroquinoline (100.0mg) and 2-amino-4-methylpyridine (57.6 mg), Pd₂dba₃ (20 mg), XantPhos(30 mg) and K₂CO₃ (270 mg) in 3 mL of t-BuOH gave compound (64) (14.0mg).

The preparation of 2-chloro-5-nitroquinoline is described in Patentapplication WO2009/23844.

Example 3 Compound (110) of Table I

According to route (A), a mixture of 8-bromo-2-chloroquinoline (500 mg)and aminopyrazine (216 mg), Pd₂dba₃ (95 mg), XantPhos (120 mg) and K₂CO₃(1.15 g) in 12 mL of t-BuOH gave compound (110) (245 mg).

The preparation of 8-bromo-2-chloroquinoline is described in Cottet, F.et al. Eur. J. Org. Chem. 2003, 8, 1559.

Example 4 Compound (143) of Table I

According to route (A), a mixture of7-chloro-4-(N,N-dimethylamino)quinoline (500 mg),4-trifluoromethoxyaniline (0.257 mL), Pd₂dba₃ (110 mg), XPhos (115 mg)and K₂CO₃ (1 g) in 10 mL of t-BuOH gave compound (143) (410 mg).

The preparation of 7-chloro-4-(N,N-dimethylamino)quinoline is describedin Sanchez-Martin, R. et al. J. Med. Chem. 2005, 48, 3354.

Example 5 Compound (148) of Table I

According to route (B), a mixture of 5,8-dimethylisoquinolin-6-amine (59mg) and 2-bromo-5-methylpyridine (86 mg), Pd(OAc)₂ (2.2 mg), XantPhos(5.8 mg) and Cs₂CO₃ (456 mg) in 2 mL of t-BuOH gave compound (148) (48mg).

The preparation of 5,8-dimethylisoquinolin-6-amine is described inAustralian Journal of Chemistry 1969, 22, 2489.

1H NMR (300 MHz, CDCl3) δ 9.32 (s, 1H), 8.52 (d, J=6.0, 1H), 8.07 (s,1H), 7.72 (d, J=6.0, 1H), 7.51 (s, 1H), 7.36 (dd, J=2.1, 8.4, 1H), 6.69(d, J=8.3, 2H), 2.72 (s, 3H), 2.48 (s, 3H), 2.26 (s, 3H)

MS (ESI) [M+H]+=264

Example 6 Pharmacological Data

Standard Operating Procedure:

Effect of drug compounds on invasion of MDA-MB231-D3H2LN cells intocollagen

Background:

A key step in the generation of tumor metastasis is tumor cell invasionof the extracellular matrix, a major component of which is collagen.Therefore, the invasion of tumor cells into collagen in vitro may beindicative of tumor metastasis in vivo. E.g., MDA-MB231-luc-D3H2LN mousebreast cancer cells display both higher invasion into collagen in vitroand a higher metastatic potential in vivo as compared to MDA-MB231 cells(from which they were derived). Using these MDA-MB231-luc-D3H2LN cellsas a model, the aim of the experiment described here is to identify drugcompounds that inhibit the invasion of tumor cells into collagen invitro, therefore potentially inhibiting also the generation of tumormetastasis in vivo.

Assay Principle:

Step 1: Preparation of cells at the bottom of a collagen gel: Cells weresuspended in a liquid collagen solution (4° C.), distributed intoBSA-coated wells, and then collected at the bottom of the wells bycentrifugation. The collagen was then solidified by incubation at 37° C.The BSA coating improves the adhesion of the collagen gel.

Step 2: Pre-treatment with the compounds to be tested: Concentrated drugsolutions were then added on top of the collagen, and cells arepre-incubated for 24 h with the drugs at low serum conditions (0.025%FBS).

Step 3: Stimulation of invasion: Medium with 5% FBS was then added inorder to stimulate invasion of the cells into the collagen gel.

Step 4: Fixation and staining: Following another 24 h incubation, cellswere fixed and nuclei were stained.

Step 5: Analysis: Finally, plates were analyzed using an automatedmicroscope. Fluorescent beads that have been included into the BSAcoating serve to detect the bottom of the wells. Pictures of the stainednuclei were taken at the same level (0 μm) as well as 25 μm and 50 μmabove.

Note:

In order to detect possible toxic effects, all compounds were tested inparallel in a viability assay. The viability assay was performed inparallel on serum-starved cells (as in the invasion assay) vs. cellsunder normal culture conditions (10% FBS).

Materials:

General Equipment: Freezer (−20° C.), refrigerator (4° C.), ice machine,water bath (37° C.), incubator (37° C./5% CO₂), cell culture hood,vortex, vacuum pump, microscope, Malassez cell, Pipet aid, micropipettes(for pipetting 1-1000 μl), multichannel pipettes (for pipetting 20-200μl), standard cell culture centrifuge, refrigerated centrifuge for 96well plates.

General Consumables: Sterile 96 well cell culture plates (for theviability assay), sterile tubes (1.5/15/50 ml), sterile pipettes(5/10/25 ml), sterile micropipette tips (for pipetting 1-1000 μl),sterile Pasteur pipettes, sterile reagent reservoirs.

General Products: Sterile PBS, sterile Milli-Q water, DMSO,decomplemented FBS (frozen aliquots), 0.1 N NaOH, 1 M Hepes, MEM withoutserum (not older than 1 month), 2.5×MEM without serum (not older than 1month), MEM with 10% FBS (not older than one month), 0.25% trypsin/1 mMEDTA solution, 37% formaldehyde solution.

Specific Equipment:

plate reader: Tecan Infinite F200

automated microscope: Cellomics ArrayScan VTI HCS Reader

Specific Consumables:

sterile black 96 well plates (for the invasion assay): Perkin ElmerViewPlate-96 F TC, ref. 6005225

sterile 96 deep well polypropylene plates (for drug preparation):Starlab, ref. S1896-5110

Specific Products:

rat tail collagen, type 1: BD Biosciences, ref. 354236 (note: each newlot has to be validated)

red fluorescent beads (1 μm diameter): Invitrogen, ref. F13083

Y-27632 (5 mM aqueous solution): Calbiochem, ref. 688001 (in solution)or 688000 (dry powder)

BSA without fatty acids (sterile-filtered 4% aqueous solution): Sigma,ref. A8806 (dry powder)

Hoechst 33342 nuclear stain (10 mg/ml): Invitrogen, ref. H3570

MTS reagent: Promega CellTiter CellTiter 96® AQueous One SolutionReagent, ref. G3581

drug compounds to be tested: generally 25 or 50 mM in 100% DMSO(aliquots stored at −20° C., then at 4° C. for max. 3 months)

MDA-MB231-luc-D3H2LN cells:

Limits for the cell cultures to be used in the assays:

total passage number: max. 30

last passage: between 2 and 4 days before, between 1:3 and 1:20

cell density: between 50 and 90% (optimally 70%) (between 1 and 2×106cells per 100 mm dish)

Experimental Procedures

General Considerations: Controls and plate maps:

Invasion assay: Negative control: No drug (just DMSO at equivalentconcentration). Positive control: 10 μM Y-27632. To avoid edge effects,only the 60 central wells B2-G11 were used; lines A and H as well ascolumns 1 and 12 remain free. Each drug was tested at least intriplicate. The positive and negative controls were tested in doubletriplicates at different positions on each plate. Typical plate map(−=negative control, +=positive control, 1-16=16 different drugcompounds):

1 2 3 4 5 6 7 8 9 10 11 12 A B − 1 2 3 4 5 6 7 8 + C − 1 2 3 4 5 6 7 8 +D − 1 2 3 4 5 6 7 8 + E + 9 10 11 12 13 14 15 16 − F + 9 10 11 12 13 1415 16 − G + 9 10 11 12 13 14 15 16 − H

Viability Assays: No additional controls. The MTS viability assay wasbased on colorimetric detection of a product generated by themitochondrial activity of the cells. Each drug was tested at least induplicate. To detect potential direct interactions with the assaysubstrate, each drug was also tested in absence of cells (backgroundsignals). Typical plate map (controls and drug compounds as in theinvasion assay, lines A-B and E-F: with cells, lines C-D and G-H:without cells; each 1 plate with 10% vs. 0.025% FBS):

1 2 3 4 5 6 7 8 9 10 11 12 A − 1 2 3 4 5 6 7 8 + B − 1 2 3 4 5 6 7 8 + C− 1 2 3 4 5 6 7 8 + D − 1 2 3 4 5 6 7 8 + E + 9 10 11 12 13 14 15 16 −F + 9 10 11 12 13 14 15 16 − G + 9 10 11 12 13 14 15 16 − H + 9 10 11 1213 14 15 16 −

The volumes or other quantities indicated in the following are requiredfor testing 16 drug compounds per 96 wells-plate at 5 μM each(+controls) in an invasion assay and each one viability assay onserum-starved cells vs. cells under normal culture conditions accordingto the plate maps above. According to the number of tested compounds,the volumes and other quantities should be adapted for testing more orless compounds or different concentrations.

Day 1: Preparation and Treatment of the Cells (all Steps are PerformedUnder a Cell Culture Hood):

Preparation of 100× concentrated drug solutions in 10% DMSO:

prepare 10% DMSO in sterile PBS: 1.8 ml sterile PBS+0.2 ml DMSO

prepare 100 μl/well 10% DMSO in PBS in 16 wells of a sterile 96 wellpolypropylene plate

add each 1 or 2 μl of the 50 or 25 mM compound stock solutions,respectively

mix by pipetting up and down

Preparation of 4× concentrated drug and control solutions in 0.4% DMSOin MEM+0.1% FBS:

Prepare MEM+0.1% FBS: 12 ml MEM without serum+12 μl FBS (freshly thawedaliquot)

prepare 480 μl/well MEM+0.1% FBS in 20 wells of a sterile 96 deep wellpolypropylene plate

negative controls (no drug): add each 20 μl 10% DMSO in sterile PBS

positive controls (Y-27632): add each 14 μl sterile PBS+2 μl DMSO+4 μl+5mM Y-27632 (freshly thawed aliquot)

drug compounds: add each 20 μl of the 100× concentrated drug solutionsin 10% DMSO

mix by pipetting up and down

store at RT until use

Coating of the Plates for the Invasion Assay:

mix 9.5 ml MEM without serum+0.5 ml 4% BSA without fatty acids+1 μlvortexed fluorescent beads (i.e. dilute 1:10000), vortex, distribute 100μl/well into the plate for the invasion assay

centrifuge 30′ with 1800×g at 4° C. (e.g. 3000 rpm in a Jouan GR412centrifuge)

remove supernatants by aspiration

Preparation of a 10×106 Cells/Ml Cell Suspension (During theCentrifugation of the Plates):

remove medium, wash cells with ˜10 ml/dish PBS, add 1 ml/dish 0.25%trypsin/1 mM EDTA

incubate 30-60 s at 37° C.

add 5-10 ml/dish pre-warmed MEM+10% FBS

homogenize by pipetting up and down using a 10 ml pipette, pool all

count cells using a Malassez cell

centrifuge 2×106 (or more) cells for 5′ with 150×g at RT (850 rpm in astd. cell culture centrifuge)

remove supernatant, resuspend cell pellet in 0.2 ml (or more,respectively) MEM without serum, yielding 10×106 cells/ml

Preparation of the Invasion Assay (on Ice; Start During theCentrifugation of the Cells):

mix on ice in a pre-chilled tube: example for a 3.4 mg/ml collagen stocksolution; volumes of collagen and water to be adapted according to thestock concentration of each collagen lot:

2.8 ml 2.5×MEM

441 μl water

140 μl M Hepes

49 μl N NaOH

3.5 ml 3.4 mg/ml collagen stock solution (yielding 1.7 mg/ml collagen in7 ml)

homogenize by pipetting gently up and down (keep on ice)

add 70 μl of the 10×106 cells/ml cell suspension, homogenize bypipetting gently up and down (yields 0.1×106 cells/ml in 1.7 mg/mlcollagen in 7 ml 1×MEM+20 μM Hepes) (keep on ice)

distribute 100 μl/well (i.e. 10000 cells/well) into the coated wells ofthe plate for the invasion assay (all on ice)

centrifuge 5′ with 200×g at 4° C. (e.g. 1000 rpm in a Jouan GR412centrifuge)

add 200 μl/well PBS to all free wells

incubate 30′ at 37° C./5% CO₂ (solidification of the collagen)

Preparation of the Viability Assay on Serum-Starved Cells:

add 50 μl of the 10×106 cells/ml cell suspension to 5 ml MEM withoutserum (yields 0.1×106 cells/ml)

distribute 100 μl/well of this suspension (i.e. 10000 cells/well) or MEMwithout serum without cells, respectively, into a standard 96 welltissue culture plate, according to the plate map above

add 200 μl/well PBS to all free wells

incubate 30′ at 37° C./5% CO₂

Preparation of the Viability Assay on Cells Under Normal CultureConditions:

add 30 μl of the 10×106 cells/ml cell suspension to 5 ml MEM+10% FBS(yields 0.06×106 cells/nil)

distribute 100 μl/well of this suspension (i.e. 6000 cells/well) orMEM+10% FBS without cells, respectively, into a standard 96 well tissueculture plate, according to the plate map above

add 200 μl/well PBS to all free wells

incubate 30′ at 37° C./5% CO₂

Treatment with the Drugs:

add each 33 μl/well of the 4× concentrated drug solutions in MEM+0.1%FBS to the corresponding wells in all three plates, according to theplate maps above

incubate 24 h at 37° C./5% CO₂

Day 2: Addition of FBS to Stimulate the Invasion:

Microscopic Observation after 24 h of Treatment:

examine the cells of the viability assays

Addition of FBS (Under a Cell Culture Hood):

prepare MEM+5% FBS: 7.2 ml MEM without serum+0.8 ml FBS (freshly thawedaliquot or rest of the aliquot thawed the day before if kept at 4° C.)

add 33 μl/well to all wells of invasion and viability assays

incubate 24 h at 37° C./5% CO₂

Day 3: Stop:

Microscopic Observation after 48 h of Treatment:

examine the cells of the viability assays

Viability Assays: MTS Assay:

add each 33 μl/well of the MTS reagent, incubate 2.5 h at 37° C./5% CO₂

shake and read absorbance at 490 nm (proportional to the viability)

calculate the background-corrected signals by subtracting the means ofthe background signals in absence of cells from the correspondingsignals in presence of cells

normalize the background-corrected signals with respect to the meansignal of the negative controls (no drug) (viabilities are thusexpressed in “% of control”)

Invasion Assays: fixation and staining (formaldehyde must be manipulatedunder a fume cupboard):

freshly prepare 1 μg/ml Hoechst 33342 in 18.5% formaldehyde: 5 ml PBS(not necessarily sterile)+5 ml 37% formaldehyde+1 μl 10 mg/ml Hoechst33342 (note: for one plate, a smaller volume would be sufficient, butthe minimal pipetted volume should not be below 1 μl)

add 50 μl/well to all wells of the invasion assay (yields 4.3%formaldehyde final)

seal with black film (provided with the plates)

incubate at least 7 h at RT

Day 3: 17 (Min 7 h/Max. 2 Weeks after Fixation and Staining): Analysisof the Invasion Assay:

Lecture using the Cellomics ArrayScan VTI HCS Reader:

BioApplication: SpotDetector.V3

Plate type: Perkin Elmer 96 well

Parameters of the Assay Protocol:

objective: 10× (NA 0.45)

apotome: yes (resulting optical slice: 11.7 μM)

fields per well: 8

autofocus in each field

autofocus channel: 1

channel 1 (autofocus on, and photo of the fluorescent beads at thebottom of the wells): filter: XF93-TRITC; exposure time: usually between0.002 and 0.01 s

channel 2 (photo of the stained cells at the same level as thefluorescent beads): filter: XF100-Hoechst; exposure time: usuallybetween 0.02 and 0.1 s; z offset: 0 μM

channel 3 (photo of the stained cells 25 μM above the fluorescentbeads): filter: XF100-Hoechst; exposure time: usually between 0.02 and0.1 s; z offset: −25 μM

channel 4 (photo of the fluorescent cells 50 μM above the fluorescentbeads): filter: XF100-Hoechst; exposure time: usually between 0.02 and0.1 s; z offset: −50 μM

object identification: method: fixed threshold: 100-32767

object selection parameters: min. max. SpotArea: 20 1000000000000SpotShapeBFR: 0.2 1000 SpotShapeBAR: 0 1000 SpotAvgInten: 200 32767SpotTotalInten: ≦4000 (thus 1000000000000 not limiting) TargetAvgInten:0 32767 TargetTotalInten: 0 1000000000000

Analysis of the Results of the Scan Using vHCS Viewer:

export the results: for each well:

number of valid fields

number of objects in each valid field in each of the channels 2, 3 and 4(“field details”)

mean numbers of objects per valid field for each well, in each of thechannels 2, 3 and 4

exclude wells with less than 6 valid fields per well from furtheranalysis

visually check all photos for any apparent problems, such as badfocusing or obviously inhomogeneous collagen structure (“bubbles”, . . .), . . . ; in case of apparent problems: document, then exclude thecorresponding wells from further analysis

Further Analysis of the Results of the Invasion Assay (Using e.g.Excel):

For each well, the mean invasion distance was calculated as follows: (25μm×number of cells at 25 μm+50 μm×number cells at 50 μm)/sum of cells at0, 25 and 50 μm

For all four parameters (number of cells at 0 μm, number of cells at 25μm, number of cells at 50 μm, mean invasion distance of the countedcells), calculate means, SD and CV of the replicates (n=6 for thecontrols; n=3 for the samples).

Replicates having a CV ≧50% (compound to be re-tested, or assay to berepeated if CV ≧50% for the untreated negative control or the compoundY-27632-treated positive control) were invalidated. Y27632 is aselective inhibitor of the Rho-associated protein kinase p160ROCK of thefollowing formula:

The assay was validated only if the mean invasion distance of the cellstreated with 10 μM Y-27632 (positive control) was decreased by ≧40% ascompared to the untreated negative control.

Graphs were plotted of all four parameters (number of cells at 0 μm,number of cells at 25 μm, number of cells at 50 μm, mean invasiondistance of the counted cells).

Results

Anti-invasive effect at 5 μM on MDA-MB231 breast cancer cells (foldeffect compared to 10 μM Y-27632 ref. compound)

Compound Invasion of MDA MB231 cells at 5 mM (family) (fold effect ofpositive control) 148 (Iee) 0.54 109 (Ie) 0.41 110 (Ie) 0.64 112 (Ie)0.26 143 (Iq) 0.8 144 (Iq) 0.73 63 (Ia) 0.69 64 (Ia) 1.16 6 (Ia) 0.63 18(Ia) 0.52 45 (Ia) 0.50 30 (Ia) 0.33 35 (Ia) 0.26 36 (Ia) 0.43 37 (Ia)0.34 48 (Ia) 0.63 53 (Ia) 0.27 51 (Ia) 1.06 52 (Ia) 0.27 58 (Ia) 0.33 61(Ia) 0.34 58 (Ia) 0.33 55 (Ia) 0.27 56 (Ia) 0.26

The compounds according to the present invention demonstrated ananti-invasive effect predictive for their activity against cancer.

Therefore, the results of the tests carried out with the compoundsdescribed herein demonstrated properties that may be useful to inhibit,prevent and/or treat cancer. For example, the following types of cancersmay more be treated by the compounds according to the present invention:colorectal cancer, pancreatic cancer, lung cancer including non-smallcell lung cancer, breast cancer, bladder cancer, gall bladder cancer,thyroid cancer, melanoma, liver cancer, uterine/cervical cancer,oesophageal cancer, kidney cancer, ovarian cancer, prostate cancer, headand neck cancer, and stomach cancer, etc. For this purpose an effectiveamount of a said compound may be administered to a patient sufferingfrom cancer.

The present disclosure is also related to the use of at least a compoundchosen among a compound of anyone of formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip),(Ig), (Ir) or (Iee) as defined above, and compounds (1) to (168) asdefined above, or one of its pharmaceutically acceptable salts accordingto the present invention for the manufacture of a pharmaceuticalcomposition intended for the treatment of cancer.

The present disclosure also encompasses pharmaceutical compositionscomprising at least a compound chosen among new compounds of formula(Ig) or (Iee) as defined above and compounds (143), (144), (149), (166)and (167) as defined above or any pharmaceutically acceptable saltthereof.

Thus, these pharmaceutical compositions contain an effective amount ofsaid compound, and one or more pharmaceutical excipients.

The aforementioned excipients are selected according to the dosage formand the desired mode of administration.

In this context, the compounds described herein can be present in anypharmaceutical form suitable for enteral or parenteral administration,in association with appropriate excipients, for example in the form ofplain or coated tablets, hard gelatine, soft shell capsules and othercapsules, suppositories, or drinkable, such as suspensions, syrups, orinjectable solutions or suspensions, in doses which enable the dailyadministration of from 0.1 to 1000 mg of active substance.

The present disclosure is also related to the use of a compound ofanyone of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih),(Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) or (Iee) as definedabove, and compounds (1) to (168) as defined above, or one of itspharmaceutically acceptable salts according to the present invention forthe manufacture of a pharmaceutical composition intended for inhibiting,preventing and/or treating cancer.

The present disclosure further relates to a method of treatment ofpatients suffering from cancer, which comprises at least a step ofadministration to a patient suffering thereof of an effective amount ofa compound of anyone of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If),(Ig), (Ih), (Ii), (Ij), (Ik), (Ii), (Im), (Io), (Ip), (Iq), (Ir) or(Iee) as defined above and (1) to (168) or one of its pharmaceuticallyacceptable salts.

What is claimed is:
 1. A compound having the following formula or apharmaceutically acceptable salt thereof:

wherein: R independently represent a hydrogen atom, a halogen atom, a—CN group, a hydroxyl group, a —COOR₁ group, a (C₁-C₃)fluoroalkyl group,a (C₁-C₃)fluoroalkoxy group, a —NO₂ group, a —NR₁R₂ group, a(C₁-C₄)alkoxy group, a phenoxy group, or a (C₁-C₃)alkyl group optionallymono-substituted by a hydroxyl group, R₁ and R₂ are independently ahydrogen atom or a (C₁-C₃)alkyl group, n is 1, 2, or 3, n′ is 1 or 2, R′is a hydrogen atom, a halogen atom, a (C₁-C₃)alkyl group, a hydroxylgroup, a —COOR₁ group, a —NO₂ group, a —NR₁R₂ group, a morpholinylgroup, a morpholino group, a N-methylpiperazinyl group, a(C₁-C₃)fluoroalkyl group, a (C₁-C₄)alkoxy group, or a —CN group, and R″is a hydrogen atom or a (C₁-C₄)alkyl group, with the proviso that: R′and R are not simultaneously a hydrogen atom, when R′ is a hydrogenatom, R is not a —NO₂ group or a —NH₂ group, and when n is 2 and R′ is ahydrogen atom, R is not a COOC₂H₅ group or a chlorine atom.
 2. Thecompound of claim 1, wherein R is a (C₁-C₃)fluoroalkoxy group.
 3. Thecompound of claim 1, wherein R′ is a —NR₁R₂ group.
 4. The compound ofclaim 1, wherein R′ is a morpholinyl, a morpholino group, or aN-methylpiperazinyl group.
 5. A compound selected from the groupconsisting of: (143)4-N,4-N-dimethyl-7-N[4-(trifluoromethoxy)phenyl]quinoline-4,7-diamine;(144) 4-(morpholin-4-yl)-N-[4-(trifluoromethoxy)phenyl]quinolin-7-amine;(166) N-(4-methoxyphenyl)-4-(4-methylpiperazin-1-yl)quinolin-7-amine;(167) 4-methoxy-N[4-(trifluoromethoxy)phenyl]quinolin-7-amine; or theirpharmaceutically acceptable salts.
 6. The compound of claim 5, whereinthe pharmaceutically acceptable salts are selected from hydrobromide,citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate,maleate, mesylate, formate, acetate or fumarate.
 7. A pharmaceuticalcomposition comprising at least one compound as defined in claim
 1. 8. Apharmaceutical composition comprising at least one compound as definedin claim
 2. 9. A pharmaceutical composition comprising at least onecompound as defined in claim
 3. 10. A pharmaceutical compositioncomprising at least one compound as defined in claim
 4. 11. Apharmaceutical composition comprising at least one compound as definedin claim
 5. 12. A pharmaceutical composition comprising at least onecompound as defined in claim
 6. 13. The pharmaceutical compositionaccording to claim 7, further comprising a pharmaceutically acceptablesupport.
 14. The pharmaceutical composition according to claim 8,further comprising a pharmaceutically acceptable support.
 15. Thepharmaceutical composition according to claim 9, further comprising apharmaceutically acceptable support.
 16. The pharmaceutical compositionaccording to claim 10, further comprising a pharmaceutically acceptablesupport.
 17. The pharmaceutical composition according to claim 11,further comprising a pharmaceutically acceptable support.
 18. Thepharmaceutical composition according to claim 12, further comprising apharmaceutically acceptable support.
 19. A method of treating cancerselected from the group consisting of breast cancer, pancreatic cancer,prostate cancer, lung cancer, non-small cell lung cancer, thyroidcancer, liver cancer, and kidney cancer, comprising: contacting a cellwith at least one compound of formula (Iq) or a pharmaceuticallyacceptable salt thereof:

wherein: R independently represent a hydrogen atom, a halogen atom, a—CN group, a hydroxyl group, a —COOR₁ group, a (C₁-C₃)fluoroalkyl group,a (C₁-C₃)fluoroalkoxy group, a —NO₂ group, a —NR₁R₂ group, a(C₁-C₄)alkoxy group, a phenoxy group, or a (C₁-C₃)alkyl group optionallymono-substituted by a hydroxyl group, R₁ and R₂ are independently ahydrogen atom or a (C₁-C₃)alkyl group, n is 1, 2, or 3, n′ is 1 or 2, R′is a hydrogen atom, a halogen atom, a (C₁-C₃)alkyl group, a hydroxylgroup, a —COOR₁ group, a —NO₂ group, a —NR₁R₂ group, a morpholinylgroup, a morpholino group, a N-methylpiperazinyl group, a(C₁-C₃)fluoroalkyl group, a (C₁-C₄)alkoxy group, or a —CN group, and R″is a hydrogen atom or a (C₁-C₄)alkyl group.
 20. The method of claim 19,wherein: R independently represent a hydrogen atom, a (C₁-C₃)alkoxygroup, or a (C₁-C₃)fluoroalkoxy group, and R′ is a hydrogen atom, a—NR₁R₂ group, a N-methylpiperazinyl group, a (C₁-C₃)alkoxy group, or amorpholino group.
 21. The method of claim 19, wherein R is a(C₁-C₃)fluoroalkoxy group.
 22. A method of treating cancer selected fromthe group consisting of breast cancer, pancreatic cancer, prostatecancer, lung cancer, non-small cell lung cancer, thyroid cancer, livercancer, and kidney cancer comprising contacting a cell with at least onecompound selected from the group consisting of: (143)4-N,4-N-dimethyl-7-N[4-(trifluoromethoxy)phenyl]quinoline-4,7-diamine;(144) 4-(morpholin-4-yl)-N-[4-(trifluoromethoxy)phenyl]quinolin-7-amine;(166) N-(4-methoxyphenyl)-4-(4-methylpiperazin-1-yl)quinolin-7-amine;(167) 4-methoxy-N[4-(trifluoromethoxy)phenyl]quinolin-7-amine; orpharmaceutically acceptable salts thereof.
 23. The method of claim 22,wherein the pharmaceutically acceptable salts are selected fromhydrobromide, citrate, trifluoroacetate, ascorbate, hydrochloride,tartrate, triflate, maleate, mesylate, formate, acetate, or fumarate.24. The method of claim 19, further comprising a step of administeringthe compound to a patient in need of cancer treatment.
 25. The method ofclaim 24, wherein the compound is administered to the patient orally.26. The method of claim 22, further comprising a step of administeringthe compound to a patient in need of cancer treatment.
 27. The method ofclaim 26, wherein the compound is administered to the patient orally.